US20200384062A1 - Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation - Google Patents
Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation Download PDFInfo
- Publication number
- US20200384062A1 US20200384062A1 US16/994,283 US202016994283A US2020384062A1 US 20200384062 A1 US20200384062 A1 US 20200384062A1 US 202016994283 A US202016994283 A US 202016994283A US 2020384062 A1 US2020384062 A1 US 2020384062A1
- Authority
- US
- United States
- Prior art keywords
- cathepsin
- psoriasis
- inhibitor
- elastase
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012545 processing Methods 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 230000002797 proteolythic effect Effects 0.000 title claims abstract description 46
- 239000003112 inhibitor Substances 0.000 title claims description 21
- 206010061218 Inflammation Diseases 0.000 title abstract description 36
- 230000004054 inflammatory process Effects 0.000 title abstract description 36
- 230000009467 reduction Effects 0.000 title abstract description 17
- 108091007973 Interleukin-36 Proteins 0.000 claims abstract description 236
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 102000035195 Peptidases Human genes 0.000 claims description 155
- 108091005804 Peptidases Proteins 0.000 claims description 155
- 239000004365 Protease Substances 0.000 claims description 153
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 120
- 238000003776 cleavage reaction Methods 0.000 claims description 95
- 230000007017 scission Effects 0.000 claims description 95
- 230000004913 activation Effects 0.000 claims description 77
- 239000003795 chemical substances by application Substances 0.000 claims description 76
- 108090000617 Cathepsin G Proteins 0.000 claims description 72
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 67
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 65
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 65
- 210000000440 neutrophil Anatomy 0.000 claims description 61
- 201000004681 Psoriasis Diseases 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000003902 Cathepsin C Human genes 0.000 claims description 30
- 108090000267 Cathepsin C Proteins 0.000 claims description 30
- 230000002757 inflammatory effect Effects 0.000 claims description 29
- 230000003213 activating effect Effects 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 24
- 235000018102 proteins Nutrition 0.000 claims description 24
- 108090000625 Cathepsin K Proteins 0.000 claims description 22
- 102000004171 Cathepsin K Human genes 0.000 claims description 22
- 201000004624 Dermatitis Diseases 0.000 claims description 21
- 239000003001 serine protease inhibitor Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 208000017520 skin disease Diseases 0.000 claims description 15
- 239000012190 activator Substances 0.000 claims description 13
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 12
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 10
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 10
- 150000003384 small molecules Chemical group 0.000 claims description 10
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 10
- 101000960215 Momordica charantia Elastase inhibitor 4 Proteins 0.000 claims description 9
- 208000023368 generalized pustular psoriasis Diseases 0.000 claims description 9
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 claims description 9
- 229940122079 Cathepsin G inhibitor Drugs 0.000 claims description 8
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims description 8
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims description 8
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims description 8
- FWIVDMJALNEADT-SFTDATJTSA-N (2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1s)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide Chemical compound C1=CC([C@H](N[C@@H](CC(C)(F)C)C(=O)NC2(CC2)C#N)C(F)(F)F)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 FWIVDMJALNEADT-SFTDATJTSA-N 0.000 claims description 6
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229940126522 cathepsin G inhibitor I Drugs 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 239000011775 sodium fluoride Substances 0.000 claims description 5
- 235000013024 sodium fluoride Nutrition 0.000 claims description 5
- 229940122858 Elastase inhibitor Drugs 0.000 claims description 4
- 201000005708 Granuloma Annulare Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000003602 elastase inhibitor Substances 0.000 claims description 4
- 206010018797 guttate psoriasis Diseases 0.000 claims description 4
- 206010021198 ichthyosis Diseases 0.000 claims description 4
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 208000008588 molluscum contagiosum Diseases 0.000 claims description 4
- LLCRBOWRJOUJAE-UHFFFAOYSA-N n-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide Chemical compound C1CN(CCC)CCN1C1=CC=C(C(=O)NC2(CCCCC2)C(=O)NCC#N)C=C1 LLCRBOWRJOUJAE-UHFFFAOYSA-N 0.000 claims description 3
- BXZBNVSSBNQNPK-UHFFFAOYSA-N n-[1-[(2-ethyl-4-oxooxolan-3-yl)carbamoyl]cyclohexyl]-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide Chemical compound CCC1OCC(=O)C1NC(=O)C1(NC(=O)C=2C=CC(=CC=2)C=2N=C(SC=2)N2CCN(C)CC2)CCCCC1 BXZBNVSSBNQNPK-UHFFFAOYSA-N 0.000 claims description 3
- 229950009755 odanacatib Drugs 0.000 claims description 3
- 229950001536 balicatib Drugs 0.000 claims description 2
- 102000004173 Cathepsin G Human genes 0.000 claims 2
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims 2
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims 2
- 206010015278 Erythrodermic psoriasis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000000770 proinflammatory effect Effects 0.000 abstract description 6
- 235000019419 proteases Nutrition 0.000 description 89
- 102100025975 Cathepsin G Human genes 0.000 description 69
- 108090000695 Cytokines Proteins 0.000 description 56
- 102000004127 Cytokines Human genes 0.000 description 55
- 210000003491 skin Anatomy 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 37
- 210000002510 keratinocyte Anatomy 0.000 description 36
- 238000002965 ELISA Methods 0.000 description 29
- 230000001185 psoriatic effect Effects 0.000 description 29
- 239000012228 culture supernatant Substances 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 201000008752 progressive muscular atrophy Diseases 0.000 description 21
- -1 PUVA treatment) Chemical compound 0.000 description 19
- 102000012479 Serine Proteases Human genes 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 108010022999 Serine Proteases Proteins 0.000 description 18
- 238000003119 immunoblot Methods 0.000 description 18
- 238000004448 titration Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 102000005927 Cysteine Proteases Human genes 0.000 description 15
- 108010005843 Cysteine Proteases Proteins 0.000 description 15
- 230000003278 mimic effect Effects 0.000 description 15
- 230000017854 proteolysis Effects 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 12
- 102000003952 Caspase 3 Human genes 0.000 description 12
- 108090000397 Caspase 3 Proteins 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 102000005600 Cathepsins Human genes 0.000 description 10
- 108010084457 Cathepsins Proteins 0.000 description 10
- 108050003558 Interleukin-17 Proteins 0.000 description 10
- 102000013691 Interleukin-17 Human genes 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 9
- 239000000816 peptidomimetic Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- IJPNNYWHXGADJG-GUBZILKMSA-N Arg-Ala-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O IJPNNYWHXGADJG-GUBZILKMSA-N 0.000 description 8
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000007385 chemical modification Methods 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010039627 Aprotinin Proteins 0.000 description 7
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 description 7
- 101710201977 Interleukin-1 receptor-like 2 Proteins 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000002427 irreversible effect Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101001050039 Homo sapiens Anosmin-1 Proteins 0.000 description 6
- 102000039996 IL-1 family Human genes 0.000 description 6
- 108091069196 IL-1 family Proteins 0.000 description 6
- 102100023012 Kallistatin Human genes 0.000 description 6
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 6
- 102000008847 Serpin Human genes 0.000 description 6
- 108050000761 Serpin Proteins 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000011535 reaction buffer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 4
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 4
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LPHGXOWFAXFCPX-KKUMJFAQSA-N Glu-Pro-Phe Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O LPHGXOWFAXFCPX-KKUMJFAQSA-N 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940099539 IL-36 receptor antagonist Drugs 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 108010028275 Leukocyte Elastase Proteins 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102100033174 Neutrophil elastase Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 101150055276 ced-3 gene Proteins 0.000 description 4
- 239000013000 chemical inhibitor Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 3
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical class ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 3
- 208000011594 Autoinflammatory disease Diseases 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000010305 Epidermal Cyst Diseases 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 3
- 101000998126 Homo sapiens Interleukin-36 beta Proteins 0.000 description 3
- 101000998124 Homo sapiens Interleukin-36 gamma Proteins 0.000 description 3
- 102100027612 Kallikrein-11 Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 101710152431 Trypsin-like protease Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001299 aldehydes Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002901 elastaselike Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 108010085906 glycylphenylalanine diazomethyl ketone Proteins 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000026721 nail disease Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010000349 Acanthosis Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- HCZXHQADHZIEJD-CIUDSAMLSA-N Ala-Leu-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HCZXHQADHZIEJD-CIUDSAMLSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710125298 Beta-defensin 2 Proteins 0.000 description 2
- 102100038326 Beta-defensin 4A Human genes 0.000 description 2
- 101710176951 Beta-defensin 4A Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940122524 Cathepsin C inhibitor Drugs 0.000 description 2
- 101710130450 Chelonianin Proteins 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000015539 Interleukin-36 alpha Human genes 0.000 description 2
- 108050004801 Interleukin-36 alpha Proteins 0.000 description 2
- 102100033498 Interleukin-36 beta Human genes 0.000 description 2
- 102100033503 Interleukin-36 gamma Human genes 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 2
- 108010066321 Keratin-14 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 241000579835 Merops Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 108091005501 Threonine proteases Proteins 0.000 description 2
- 102000035100 Threonine proteases Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- NENCFBUASFVKCT-NYLVQANASA-N biotin-valyl-alanyl-aspartyl-fluoromethyl ketone Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)CF)SC[C@@H]21 NENCFBUASFVKCT-NYLVQANASA-N 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 230000002849 elastaseinhibitory effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 230000014725 late viral mRNA transcription Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000007388 punch biopsy Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
- GZDRODOYEFEHGG-NUDCOPPTSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]propan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 GZDRODOYEFEHGG-NUDCOPPTSA-N 0.000 description 1
- QQAHEGDXEXIQPR-UHFFFAOYSA-N 2-(ethylamino)-1-phenylpentan-1-one Chemical compound CCCC(NCC)C(=O)C1=CC=CC=C1 QQAHEGDXEXIQPR-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- 108091005504 Asparagine peptide lyases Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 102000018755 Calgranulin B Human genes 0.000 description 1
- 108010052495 Calgranulin B Proteins 0.000 description 1
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 1
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
- 102100028908 Cullin-3 Human genes 0.000 description 1
- 101710094482 Cullin-3 Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000031455 DITRA Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 102100032262 E2F-associated phosphoprotein Human genes 0.000 description 1
- 101710155837 E2F-associated phosphoprotein Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002149 Elafin Human genes 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001467044 Groundnut rosette assistor virus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108050003379 Interleukin-36 beta Proteins 0.000 description 1
- 101710195086 Interleukin-36 gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- 206010048649 Koebner phenomenon Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102220503506 N-terminal kinase-like protein_F53A_mutation Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 description 1
- 101710174704 Subtilisin-like serine protease Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108010058883 acetyl-aspartyl-glutamyl-valyl-aspartyl-amino-4-methylcoumarin Proteins 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048133 human IL1RL2 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 108010072992 human interleukin-36 receptor Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003614 protease activity assay Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000007798 pustular psoriasis 14 Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220065927 rs794726936 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940026191 topical antipsoriatics tars Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Definitions
- This invention relates to the use of an agent capable of inhibiting interleukin-36 (IL-36) proteolytic processing for the treatment and/or reduction of inflammation in a subject.
- the invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.
- IL-36 interleukin-36
- Inflammation of barrier organs, including the gut, lung and skin can result in many undesirable chronic long term conditions including inflammatory skin conditions, inflammatory bowel disease and associated conditions of Crohn's disease, ulcerative colitis, and colorectal cancer and chronic obstructive pulmonary disease. These conditions tend to be difficult to treat and costly from both a long-term management and healthcare perspective. New ways of effectively treating these chronic and long-term conditions are of great importance.
- Inflammation of barrier organs in a subject includes inflammation of the skin, gut and/or lung.
- inflammatory skin conditions typically present as heterogenous conditions with disease subtypes displaying varying degrees of severity, from mild itching to grave medical health complications. They are characterized by irritation and excessive inflammation of the skin. These diseases may sometimes be disfiguring and can cause great discomfort to the affected individual.
- Inflammatory skin conditions include psoriasis such as plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, palmoplanter pustulosis, psoriatic nail disease, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis, acne and ichthyosis vulgaris.
- psoriasis such as plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, palmoplanter pustulosis, psoriatic nail disease
- Psoriasis is a common inflammatory skin condition that effects approximately 1-3% of the Caucasian population 3 .
- the most prevalent form of this condition, plaque psoriasis accounts for approximately 80% of cases.
- the related, psoriatic arthritis is encountered in 5-30% of individuals.
- Palmoplanter psoriasis is encountered in about 10% of psoriasis patients and a life-threatening severe form of psoriasis, Generalized Pustular Psoriasis (GPP), accounts for less than 5% of cases 3 .
- GPP Generalized Pustular Psoriasis
- Psoriasis is characterised by hyperproliferation and impaired differentiation of keratinocytes, the most abundant cell type in the skin, leading to thickening of the skin in lesional areas (acanthosis). It is well established that psoriasis features excessive inflammatory reactions in the skin, as a result of innate as well as adaptive immune cell types that result in the pathological features of psoriasis. While the triggering events remain unclear, skin damage, viral and bacterial infection (e.g streptococcal bacteria in the throat) and inherited genetic susceptibilities are all major factors 4-5 .
- psoriasis Current treatment for psoriasis include the use of agents such as anthralin (dihydroxyanthralin), azarabine, colchicine, fluorouracil, methotrexate, methoxsalen (8-methoxypsoralen), resorcinol, retinoids (for example, retinoic acid), corticosteroids (for example, clobetasol propionate, trimcinolone acetonide and the like), cyclosporin, iodochlorhydroxyquin, salicyclic acid, vitamin D, dapsone, somatostatin, sulfur, tars and zinc oxide.
- agents such as anthralin (dihydroxyanthralin), azarabine, colchicine, fluorouracil, methotrexate, methoxsalen (8-methoxypsoralen), resorcinol, retinoids (for example, retinoic acid), corticosteroids
- Ultra-violet light treatment alone or in combination with other agents such as psoralen (i.e., PUVA treatment), is also used to treat psoriasis 3 .
- PUVA treatment i.e., Ultra-violet light treatment
- Cytokine-targeted biologics are highly specific with minimal off-target effects or toxicity. As a consequence, there has been a revolution in the development of cytokine-targeted biological therapies using neutralizing antibodies or receptor-IgFc fusion proteins over the past decade.
- TNF neutralization has been transformative in the treatment of several inflammatory diseases 6-7 , and neutralization approaches targeted against IL-12/IL-23, IL-17, and IL-4 have entered the clinic or are on clinical trials at present.
- IL-12/IL-23 and IL-17 neutralizing antibodies have shown great efficacy in the treatment of moderate to severe forms (>10% surface area affected) of psoriasis during clinical trials 8 .
- IL-1 family cytokines which include the recently described IL-36 ⁇ , ⁇ and ⁇ proteins, play major roles as initiators of inflammation and are frequently among the first cytokines produced in response to infection or injury 8-11 .
- IL-1 cytokines are capable of triggering complex cascades of additional cytokine production from diverse cells types, such as resident tissue macrophages and dendritic cells, as well as keratinocytes and endothelial cells lining local blood vessels 12-14 .
- IL-36 ⁇ , IL-361 ⁇ and IL-36 ⁇ are encoded by distinct genes and evidence is rapidly accumulating to suggest that these cytokines play a key role in skin inflammation, particularly in psoriasis 15 .
- IL-36 receptor antagonist IL-36 receptor antagonist
- IL-36 ⁇ in the mouse leads to a psoriasis-like condition at birth that can be further exacerbated with the skin irritant, phorbol acetate 20-21 .
- a toll receptor agonist imiquomod
- mice can provoke psoriasis outbreaks 23 , which are increased in severity in IL-36RA ⁇ / ⁇ mice 22 .
- IL-36 ⁇ , IL-361 ⁇ and IL-36 ⁇ are all generated as leaderless cytokines that lack biological activity 24 .
- proteolytic processing of IL-36 proteins is required to unlock the pro-inflammatory potential of these cytokines, similar to other members of the IL-1 family, such as IL-1 ⁇ and IL-18.
- Sims and colleagues 24 have shown that removal of a small number of residues from the N-termini of IL-36 ⁇ , IL-368 and IL-36 ⁇ increases their biological activity by greater than 10,000-fold.
- IL-36 cytokines appear to play a key role as initiators of inflammation in the skin barrier, inhibitors of IL-36 activation are therefore likely to have considerable potential for the treatment of inflammatory skin conditions 15 .
- the present invention is directed to new and improved methods and compositions for the treatment of inflammatory conditions.
- composition comprising an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, and a suitable pharmaceutical excipient.
- a topical inflammatory skin disorder treatment composition comprising an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, and a suitable pharmaceutical excipient.
- an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, for use in the manufacture of a medicament for the treatment and/or reduction of inflammation particularly inflammatory skin disorders, in a subject.
- a method for the treatment and/or reduction of inflammation in a subject preferably inflammation of barrier organs, including inflammation of the skin, gut and/or lung, particularly inflammatory skin disorders, comprising administering an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, to a subject to result in the treatment and/or reduction of inflammation in said subject.
- physiologically acceptable excipient or “pharmaceutically acceptable excipient” herein refers to a substance devoid of any pharmacological effect of its own and which does not produce adverse reactions when administered to a mammal, preferably a human.
- Physiologically acceptable excipients are well known in the art and are disclosed, for instance in the Handbook of Pharmaceutical Excipients, sixth edition (2009), herein incorporated by reference.
- the terms “consists of”, “consisting of” are to be construed as a closed term.
- the terms “therapeutically effective amount” and “effective amount” refer to an amount sufficient to elicit the desired biological response.
- the desired biological response is to inhibit, reduce or ameliorate the severity, duration, progression, or onset of inflammation or associated disease, disorder or condition, prevent the advancement, recurrence, or progression of inflammation or associated disease, disorder or condition or a symptom associated with a disease, disorder or condition.
- the precise amount of compound administered to a subject will depend on the mode of administration, the type and severity of the disease, disorder or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs.
- Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound described herein being used. In cases where no amount is expressly noted, an effective amount should be assumed.
- the terms “treat”, “treatment” and “treating” refer to therapeutic treatments includes the reduction or amelioration of the progression, severity and/or duration of inflammation of associated disease, disorder or condition, or the amelioration of one or more symptoms (specifically, one or more discernible symptoms) of inflammation or associated disease, disorder or condition, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a compound or composition of the invention).
- the therapeutic treatment includes the amelioration of at least one measurable physical parameter of inflammation or associated disease, disorder or condition.
- the therapeutic treatment includes the inhibition of the progression of inflammation or associated condition, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both.
- the therapeutic treatment includes the reduction or stabilization of inflammation or associated disease, disorder or condition.
- the terms “subject” and “patient” are used interchangeably.
- the terms “subject” and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), specifically a “mammal” including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more specifically a human.
- the subject is a human.
- Interleukin-36 IL-36 cytokines or IL-36 includes one or more of the IL-36 isoforms, IL-36 ⁇ (IL-36A; IL-36 alpha; Interleukin-36 alpha), IL-36 ⁇ (IL-36B;IL-36 beta; Interleukin-36 beta) and/or IL-36 ⁇ (IL-36G;IL-36 gamma; Interleukin-36 gamma) and reference to IL-36 proteolytic processing includes one or more of IL-36 ⁇ , IL-36 ⁇ and/or IL-36 ⁇ proteolytic processing.
- protease cleavage site or relevant protease cleavage site refers to an IL-36 protease cleavage site which is required for activation of IL-36.
- an agent capable of inhibiting IL-36 activation that occurs via proteolytic processing for the treatment and/or reduction of inflammation in a subject.
- an agent capable of inhibiting IL-36 activation that occurs via proteolytic processing for the treatment and/or reduction of inflammation in a subject.
- the treatment and/or reduction of inflammation of the skin, gut and/or lung is contemplated, the treatment and/or reduction of inflammatory skin disorders are preferred.
- the agent of the invention prevents the production of a biologically active IL-36 by preventing the activation that occurs by proteolytic processing of IL-36, including one or more of IL-36 ⁇ , IL-36 ⁇ and/or IL-36 ⁇ , to prevent and/or reduce the pro-inflammatory effects of IL-36 including IL-36 ⁇ , IL-36 ⁇ and/or IL-36 ⁇ .
- proteases were responsible for activation of IL-36 proteins.
- neutrophil-derived proteases including serine proteases and cysteine proteases such as cathepsin G and elastase are potent IL-36, IL-36 ⁇ , IL-36 ⁇ (IL-36B) and/or IL-36 ⁇ (IL-36G), processing proteases.
- Other relevant proteases which may be targeted in the invention include cathepsin K, proteinase-3 and/or DPPI (dipeptidyl peptidase I) known as Cathepsin C.
- protease cleavage sites within the IL-36 isoforms which result in the activation of IL-36.
- Our findings suggest that the protease cleavage sites of the IL-36 isoforms may also be targeted and/or mimicked to directly inhibit IL-36 activation.
- agent of the invention may inhibit IL-36 proteolytic processing either directly or indirectly.
- Direct inhibition aims to target and/or mimic the newly identified IL-36 protease cleavage sites and/or amino acid residues downstream and/or upstream of the cleavage site.
- Indirect inhibition aims to inhibit the activity of the IL-36 activating proteases and activators thereof.
- the agent inhibits IL-36 activation by binding to the IL-36 protease cleavage sites required for activation of IL-36 (direct inhibition) and/or amino acid residues downstream and/or upstream of the cleavage site; and/or the agent prevents and/or inhibits the activity of IL-36 activating proteases or activators thereof (indirect inhibition).
- the agent may be selected from one or more of the following group a small molecule or biologics, including peptide, polypeptide, protein, siRNA, sgRNA, and antibody.
- the agent is a small molecule protease inhibitor.
- the small molecule protease inhibitor is a serine protease or cysteine protease inhibitor.
- the protease inhibitor may be selected from one or more of a cathepsin K inhibitor, cathepsin C(DPPI) inhibitor, elastase inhibitor, cathepsin-G inhibitor and proteinase-3 inhibitor.
- Suitable protease inhibitors include, but are not limited to boswellic Acids, cathepsin G inhibitor I, Elastase inhibitor IV, Sodium Fluoride, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF ⁇ HCl), phenylmethanesulfonylfluoride (PMSF), OdanacatibTM (MK-0822) (N-(1-cyanocyclopropyl)-4-fluoro-N2- ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethyl ⁇ -L-leucinamide), BalicatibTM (N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide), MV061194, AprotininTM (small protein bovine pancreatic tryps
- Optional protease inhibitors includes aspartate protease inhibitors, glutamic acid protease inhibitors, metalloprotease inhibitors, asparagine peptide lyase inhibitors.
- the agent is a peptide, derivative, peptidomimetic or combination thereof.
- the peptide comprises 3, 4, 5, 6,7, 8, 9 or 10 amino acids.
- the peptide is a tripeptide or tetrapeptide.
- the peptide is a synthetic or non-natural peptide.
- the peptide may inhibit IL-36 activation via proteolytic processing in several ways including:
- Suitable peptides include Lys-Ala-Leu (KAL); Ala-Leu-Ala (ALA); Met-Ala-Leu-Ala (MALA); Asp-Pro Gln-Arg (NPQR); Pro-Gln-Arg (PQR); Gln-Arg-Glu-Ala (QREA); Arg-Ala-Val (RAV); Gly-Arg-Ala-Val (GRAV); Ala-Val-Tyr-Gln (AVYQ); and derivatives or peptidomimetics thereof.
- Derivatives include chemically modified derivatives explained below including CMK modified peptides.
- Suitable peptides include Phe-Leu-Phe (FLF); Glu-Pro-Phe (EPF); Ala-Phe-Leu-Phe (ALPF); Lys-Ala-Leu (KAL); Arg-Ala-Val (RAV), Asp-Thr-Glu-Phe (DTEF), Ala-Pro-Leu (APL), Pro-Gln-Arg (PQR), Arg-Pro-Leu (RPL); and derivatives or peptidomimetics thereof.
- Derivatives include chemically modified derivatives explained below including chloromethyl ketones (CMK) modified peptides.
- the agent may directly inhibit IL-36 proteolytic processing by binding to the protease cleavage sites within IL-36 required for activation of IL-36 and/or competing with the IL-36 activating proteases, such as cathepsin G, elastase or cathepsin K, cathepsin C(DPPI) or proteinase-3, for binding to their respective cleavage sites within IL-36 required for activation of IL-36.
- the agent of the invention is designed to target and/or mimic the protease cleavage sites within IL-36 required for activation of IL-36 (IL-36 ⁇ , IL-36 ⁇ and/or IL-36 ⁇ ).
- the agent may also target and/or mimic one or more amino acid residues downstream and/or upstream of the protease cleavage site.
- the agent may target IL-36 ⁇ cleavage site, R (amino acid residue 5), and optionally one or more of the surrounding downstream residues N, P and/or Q (NPQR 5 ).
- the agent may target the IL-36 ⁇ cleavage site V (amino acid residue 15) and optionally one or more of the surrounding downstream residues G, R and or V (GRA V 15 ).
- the agent may target the IL-36 ⁇ cleavage site K (amino acid residue 3) and/or cleavage site A (amino acid 4) and optionally one or more of the surrounding downstream residues MEK 3 A 4 (SEQ ID No. 28).
- IL-36 ⁇ cleavage site K amino acid residue 3
- cleavage site A amino acid 4
- MEK 3 A 4 amino acid 4
- the agent targets both the cleavage site and one or more of the surrounding upstream and downstream residues, including for example, IL-36 ⁇ cleavage site NPQ R 5 EAPP (SEQ ID No. 1) or the IL-36 ⁇ cleavage sites GRA V 15 YQSM (SEQ ID No. 2) or IL-36 ⁇ cleavage sites MEK 3 A 4 LKID (SEQ ID No. 28).
- IL-36 ⁇ cleavage site NPQ R 5 EAPP SEQ ID No. 1
- the IL-36 ⁇ cleavage sites GRA V 15 YQSM SEQ ID No. 2
- IL-36 ⁇ cleavage sites MEK 3 A 4 LKID SEQ ID No. 28.
- one or more additional amino acid residue selected from G, R and/or V and one or more additional amino acid residues selected from Y, Q, S and/or M may be targeted for IL-36 ⁇ .
- one or more additional amino acid residue selected from M, E, K, and/or A and one or more additional amino acid residues selected from L, K, I, and/or D may be targeted for IL-36 ⁇
- IL-36 Full details of IL-36 including GenBank IDs and the cleavage sites are listed below. The cleavage sites within each amino acid sequence are underlined below.
- IL-366 (IL-36B) DNA and Amino Acid Sequence:
- EAAPKSYAIRDSRQMVWVLSGNSLIAAPLSRSIKPVTLHLIAC R DTEF SDKEKGNMVYLGIKGKDLCLFCAEIQGKPTLQLKEKNIMDLYVEK KAQKPFLFFHNKEGSTSVFQSVSYPGWFIATSTTSGQPIFLTKERGITNN TNFYLDSVE 157
- MEK 3 is a protease cleavage site of cathepsin-G within IL-36a, which is required for the activation of IL-36a.
- MEKA 4 is a protease cleavage site of elastase within IL-36a, which is required for the activation of IL-36a.
- agents preferably synthetic peptides, peptides derivatives and peptidomimetics thereof, which aim to target and/or mimic the IL-36 protease cleavage sites which directly inhibit IL-36 activation via proteolytic processing.
- the peptides are tri-peptide and tetra-peptides or peptides derivatives and peptidomimetics thereof which aim to target and/or mimic the IL-36 protease cleavage sites which directly inhibit IL-36 activation via proteolytic processing.
- peptides are designed to target and/or mimic the new protease cleavage sites identified.
- the peptides can be conventionally designed to target and/or mimic these new protease cleavage site using standard chemistry techniques (e.g. Thornberry et al., A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74; Nicholson et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul.
- the agents may be a peptide which mimics the protease cleavage sites within IL-36 ⁇ , IL-36 ⁇ and/or IL-36 ⁇ required for activation of IL-366, IL-36 ⁇ and/or IL-36 ⁇ and binds said protease cleavage sites to inhibit its activity; or derivatives or peptidomimetics thereof.
- Suitable peptide derivatives include chemically modified peptides. Chemical modifications to the peptides aim to increase stability and efficiency. Furthermore, the coupling or combinations of peptides using chemical linkers may also be contemplated. Chemical modifications include addition of chloromethyl ketones (CMK), fluoromethyl ketone (FMK), and aldehyde/formyl group (R-CHO) to the C-terminus (carboxyl group) to increase potency, through the formation of irreversible or reversible bonds with the target proteases active site amino acid (e.g. serine, cysteine), such that lower concentrations of peptides are required to achieve inhibition.
- CMK chloromethyl ketones
- FMK fluoromethyl ketone
- R-CHO aldehyde/formyl group
- Additional chemical modifications may include addition of protection groups to the N-terminus (amino group) to stabilizes the tri-/tetra-peptide and protect it from degradation; including N-benzyloxycarbonyl (Benzyl carbamate), butyl carbamate, Acetamide, phthalimide, benzylamine, triphenylmethylamine, benzylideneamine, p-toluenesulfonamide.
- Preferred chemical modifications or derivates include:
- Peptidomimetics are also contemplated, involving modifiying the peptides themselves or by designing an alternative compound/composition which mimics the peptide. Conventional techniques may be used to generate such peptidomimetics.
- Table 1 provides a list of exemplary tri-peptides and tetra-peptides designed to mimic the protease cleavage sites of the invention. CMK altered derivatives of these tri-peptide and tetra-peptides may also be used.
- IL-36 ⁇ NPQR-CMK Pro-Gln-Arg (PQR); IL-36 ⁇ PQR-CMK; Gln-Arg-Glu-Ala (QREA) (SEQ ID No. 31); IL-36 ⁇ QREA-CMK Arg-Ala-Val (RAV) IL-36 ⁇ RAV-CMK Gly-Arg-Ala-Val (GRAV) (SEQ ID No. 32); IL-36 ⁇ GRAV-CMK Ala-Val-Tyr-Gln (AVYQ) (SEQ ID No. 33); IL-36 ⁇ AVYQ-CMK;
- these peptides have been designed to bind and/or mimic the respective IL-36 protease active site and effectively compete with the substrate, IL-36, for proteolysis. This is governed by electrostatic interactions between the protease active site and the peptide which mimics the proteolytic cleavage site of a naturally occurring substrate. Therefore, an effective amount of these peptide this will result in reversible inhibition, as the active site of the protease will be occupied by the tri/tetra-peptide, thus protecting the substrate, IL-36, from proteolysis.
- CMK modified peptides the CMK chemical group located at the C-terminus of the peptide will similarly occupy the active site but will form a covalent bond resulting in irreversible inhibition of the protease. (REF:35)
- the agent may indirectly inhibit IL-36 proteolytic processing by preventing and/or inhibiting the activity of proteases which proteolytically process IL-36.
- the agent of the invention may be a conventional cysteine protease inhibitor or a serine protease inhibitor.
- Other proteases may be used as described above.
- cysteine proteases including cathepsin-C/DPPI and cathepsin K and the serine proteases including cathepsin G, elastase and proteinase-3 have a role in activating IL-36 via proteolytic processing.
- Serine proteases are characterised by a distinctive structure, consisting of two beta-barrel domains that converge at the catalytic active site.
- the catalytic triad of a serine protease consists of a Serine-Histidine-Aspartic acid (Ser-His-Asp), whereby the serine is the nucleophillic residue.
- Suitable serine protease inhibitors which may be used in the invention bind into the active site of the protease, typically exploiting the nucleophilic serine, either forming stable acyl intermediates (sulphonyl flourides/chlorides, phosphonates), or stable tetrahedral intermediates (aldehydes, halomethyl ketones, boronic acids.)
- serine protease inhibitors may also be utilised in the present invention.
- Suitable serine protease inhibitors may be selected from the following groups:
- one or more serine proteases selected from serine protease families S1 to S81 may be used.
- the agent of the invention may be a naturally occurring serine protease inhibitors from the serpin family and the chelonianin family.
- serpins inhibit proteases by a suicide substrate inhibition mechanism.
- the protease initially recognizes the serpin as a potential substrate using residues of the reactive center loop (RCL) and cleaves it between P1 and P1′. This cleavage allows insertion of the cleaved RCL into the ⁇ -sheet A of the serpin, dragging the protease with it and moving it over 71 ⁇ to the distal end of the serpin resulting in a 1:1 stoichiometric covalent inhibitory complex.
- the protease is distorted into a conformation, where the acyl enzyme intermediate is hydrolysed extremely slowly.
- chelonianin family include SLPI and Elafin.
- Cysteine protease are characterised by a common catalytic mechanism.
- the catalytic triad of a cysteine protease consists of a cysteine-histidine-aspartic acid (Cys-His-Asp), whereby the cysteine is the nucleophillic residue.
- cysteine proteases may work in accordance with the invention. These include naturally occurring cysteine protease inhibitors from cysteine families C1-C110 (MEROPS classification).
- the agent may be designed to prevent the binding of elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI, or other related proteases to IL-36 and to prevent conversion of IL-36 to its active form by elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI,_ or other neutrophil-derived proteases.
- cathepsin K a protease predominantly expressed in osteoclasts, can cleave and activate IL-36 ⁇ (beta) at the same residue as Cathepsin G (NPQR 5 EAAP).
- DPPI is an enzyme expressed in neutrophil granules that processes the neutrophil proteases (Elastase, Cathepsin G and proteinase 3) into fully active proteases. DPPI is responsible for the activation of a number of proteases, which include CatG, elastase, proteinase-3 granzyme A, granzyme B, granzyme C and chymase. In this manner, DPPI is an activator of IL-36 proteases.
- Dipeptide-derived diazoketones such as Gly-Phe-CHN2 (Gly-Phe-diazomethane) can be used to inhibit DPPI.
- the agent may be a conventional elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI inhibitor as highlighted in Table 2 below.
- agent of the invention may be a small molecule or a biologic including, peptides, polypeptide, protein, siRNA, antibody, and/or targeted genome editing/sgRNA e.g CRISPR-Cas system.
- sgRNA relates to the emerging CRISP/Cas9 genome editing technology.
- Agents which indirectly inhibit activation of IL-36 proteolytic processing by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof Agent Type Protease Target SERINE PROTEASE INHIBITORS (SMALL MOLECULE) Boswellic Acids Cathepsin G inhibitor (serine protease) cathepsin G inhibitor I Cathepsin G inhibitor (serine protease) Elastase inhibitor IV Elastase inhibitor (serine protease) Sodium Fluoride Ser/Thr and acidic phosphatases 4-(2-Aminoethyl) benzenesulfonyl fluoride Non-specific serine protease hydrochloride (AEBSF•HCl) inhibitor phenylmethanesulfonylfluoride (PMSF) Non-specific serine protease inhibitor dipeptide-derived diazoketones, such as DPPI/Cathepsin C inhibitor Gly-Phe
- the agent may be a small molecule or biologic inhibitor of cathepsin G and elastase is selected from known serine protease inhibitors and cathespin K inhibitors including but not limited to cathepsin G inhibitor I, Elastase inhibitor IV, Sodium Fluoride, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF ⁇ HCl), Aprotinin, Leupeptin, phenylmethanesulfonylfluoride (PMSF), Boswellic Acids, cathepsin K inhibitor 1, and/or Odanacatib (cathepsin K inhibitor).
- AEBSF ⁇ HCl 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
- PMSF phenylmethanesulfonylfluoride
- Boswellic Acids cathepsin K inhibitor 1
- Odanacatib catheps
- the agent of the invention may be a peptide from 3 to 10 amino acids in length, comprising or consisting of 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, that binds an IL-36 activating protease and/or competes with IL-36 activating proteases for access to the IL-36 cleavage sites.
- the peptide is a tripeptide or tetrapeptide, although longer peptide chains may be used.
- the peptide may be up to 8-10 amino acids in length.
- the peptide which may be a tripeptide or tetrapeptide, binds to the IL-36 neutrophil-derived protease and/or competes with neutrophil-derived proteases for access to the IL-36 neutrophil-derived protease cleavage sites.
- the peptide of the invention may be linked to form multi-peptide combinations, comprising for example from 2 to 20 tripeptide or tetrapeptide units.
- the multi-peptide combination comprises 6/8, 9/12 or 12/16 multiples of tripeptides or tetra peptides.
- the peptides may be chemically linked to form multi-peptide combinations.
- the peptides target the proteases directly.
- the peptide sequences e.g. tri/tetra peptides etc as outlined below
- the peptide sequences are designed to mimic and/or target the cleavage sites and motifs within the IL-36 proteins to act as targets for any proteases, thereby, protecting IL-36 from proteolysis.
- peptides may be designed and manufactured using standard chemistry techniques (e.g. Thornberry et al., A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74; Nicholson et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43; Powers J C et al, Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-750. (2002); Merrifield, R. B.
- CMK modified Arg-Ala-Val (RAV), Asp-Thr-Glu-Phe (DTEF), Ala-Pro-Leu (APL), Pro-Gln-Arg (PQR), Arg-Pro-Leu (RPL) are also contemplated.
- chemical modifications to the peptides aim to increase stability and efficiency. Furthermore, the coupling or combinations of peptides using chemical linkers may also be contemplated. Chemical modifications include addition of chloromethyl ketones (CMK), fluoromethyl ketone (FMK), and aldehyde/formyl group (R-CHO) to the C-terminus (carboxyl group) to increase potency, through the formation of irreversible or reversible bonds with the target proteases active site amino acid (e.g. serine, cysteine), such that lower concentrations of peptides are required to achieve inhibition.
- CMK chloromethyl ketones
- FMK fluoromethyl ketone
- R-CHO aldehyde/formyl group
- Additional chemical modifications may include addition of protection groups to the N-terminus (amino group) to stabilizes the tri-/tetra-peptide and protect it from degradation; including N-benzyloxycarbonyl (Benzyl carbamate), butyl carbamate, Acetamide, phthalimide, benzylamine, triphenylmethylamine, benzylideneamine, p-toluenesulfonamide.
- Combinations of peptides may be used that simultaneously target both elastase, cathepsin G or cathepsin K.
- candidate peptides that target both elastase and cathepsin G and/or cathepsin K may be “linked” via a chemical linker.
- the agent may chemically cross-link two or more peptides to form multi-peptide combinations
- the antibody may be a polyclonal or monoclonal antibody raised against IL-36 activating proteases, including the proteases elastase or cathepsin G, K or C. In this manner, the antibody binds to the IL-36 activating protease to prevent the protease binding to the protease cleavage sites within IL-36.
- the antibody may be a polyclonal or monoclonal antibody raised against the protease cleavage site amino acid sequence within IL-36, preferably IL-36 ⁇ and IL-36 ⁇ . In this manner, the antibody binds the amino acid sequence encompassing the protease cleavage site within IL-36 to block access of the IL-36 activating protease to the IL-36 cleavage sites.
- the present invention may be directed to the treatment of inflammation of barrier organs in a subject, including inflammation of the skin, gut and/or lung.
- the present invention may be used in the treatment of inflammatory skin disorders, such as psoriasis, including Psoriasis vulgaris, dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris.
- psoriasis including Psoriasis vulgaris, dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris.
- psoriasis including Psoriasis vulgaris, dermatitis and/or acne, sebaceous
- Psoriasis will be understood to cover all forms of psoriasis comprising psoriasis vulgaris, plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, arthritic psoriasis, palmoplanter pustulosis and psoriatic nail disease.
- composition comprising an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- the agents described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
- the present invention relates to a pharmaceutical composition comprising an agent of the invention described herein, and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
- the present invention is a pharmaceutical composition comprising an effective amount of an agent of the present invention and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
- Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
- Suitable pharmaceutical excipients include but are not limited to binders, disintegrants, fillers, flavours, colours, lubricants, glidants, sorbents and/or preservatives.
- agent capable of inhibiting IL-36 activation via proteolytic processing may be adapted for administration in the following alternative forms tablets, capsules, oral liquids, transdermal patches, injectable products, implants, eye products, nasal products, inhalers and suppositories.
- compositions of the invention can also be in liquid form, for example, solutions, emulsions, suspensions or syrups.
- the invention is also directed to agents which target and/or mimic one or more of the following IL-36 protease cleavage sites
- the invention is also directed to agents which inhibit IL-36 activation via proteolytic processing by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof selected from elastase, cathepsin G, cathepsin K, proteinase-3 and DPPI (Cathepsin C).
- the agent comprises or consists of the peptides listed in Tables 1 and 3, or derivatives, peptidomimetic or combinations thereof.
- a comprising an agent capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- the agent is as defined above, and inhibits IL-36 activation by binding to the IL-36 protease cleavage sites required for activation of IL-36; or the agent prevents and/or inhibits the activity of IL-36 activating proteases or activators thereof.
- composition is for topical treatment although other administration routes, for example oral, parenteral, intravenous are also contemplated.
- a topical inflammatory composition ideally a skin disorder treatment composition, comprising an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- the composition is adapted for the treatment and prevention of inflammatory skin disorders and comprises an agent capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- the topical treatment composition may be in the form of a cream or gel.
- the suitable pharmaceutical excipient may be any conventional topical pharmaceutical excipient.
- the agent is a small molecule, peptide, polypeptide, protein, siRNA, sgRNA, and/or antibody.
- the agent may be selected from Table 1, 2 or 3.
- an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing for use in the manufacture of a medicament for the treatment and/or reduction of inflammation, preferably inflammatory skin disorders, in a subject.
- a method for the treatment and/or reduction of inflammation in a subject comprising administering an effective amount of an agent as described above which is capable of inhibiting IL-36 proteolytic processing to a subject.
- the subject is a subject suffering from an inflammatory skin disorder selected from psoriasis, including Psoriasis vulgaris; dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris.
- an inflammatory skin disorder selected from psoriasis, including Psoriasis vulgaris; dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris.
- Psoriasis will be understood to cover all forms of psoriasis comprising psoriasis vulgaris, plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, arthritic psoriasis, palmoplanter pustulosis and psoriatic nail disease.
- the subject is ideally a mammal, preferably a human.
- the agent capable of inhibiting IL-36 proteolytic processing may be applied topically to the subject.
- FIG. 1 (A) is a schematic of modified forms of IL-36 ⁇ , IL-36 ⁇ and IL-36 ⁇ where a caspase-3-processing motif (DEVD) was inserted into the IL-36 sequence, N-terminal to the known processing sites.
- DEVD caspase-3-processing motif
- FIG. 2 are graphs showing HeLa Vector and HeLa IL36R stimulated with caspase-3 cleaved DEVD-IL36 ⁇ , ⁇ and ⁇ . After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- (B) are graphs showing HeLa IL36R stimulated with full-length or caspase-3 cleaved DEVD-IL-36 ⁇ , ⁇ and ⁇ . At indicated time-points cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 3 are graphs showing HeLa IL36R were stimulated with (A) full-length DEVD-IL-36 ⁇ or caspase-3 cleaved DEVD-IL-36 ⁇ , (B) full-length DEVD-IL-36 ⁇ or caspase-3 cleaved DEVD-IL-36 ⁇ , (C) full-length DEVD-IL-36 ⁇ or caspase-3 cleaved DEVD-IL-36 ⁇ at the indicated concentrations. (D) showing HaCat stimulated with full-length DEVD-IL-36 ⁇ or caspase-3 cleaved DEVD-IL-36 ⁇ at the indicated concentrations. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 4 are photographs showing primary blood derived neutrophils stimulated in the presence or absence of PMA (50 nM) for 3 h.
- B are graphs showing HeLa IL36R were stimulated with 500 pM IL36 ⁇ , ⁇ and ⁇ pre-incubated for 2 h at 37° with indicated dilutions of either control or PMA-activated degranulates. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 5 are graphs showing HeLa IL36R stimulated with IL36 ⁇ , IL36 ⁇ and IL36 ⁇ , pre-incubated for 2 h at 37° with neutrophils degranulates in the presence or absence of PMSF (1 mM), leupeptin (10 ⁇ g/ml), aprotinin (10 mg/ml), Cathepsin G inhibitor 1 (10 ⁇ M), zVAD-fmk (10 ⁇ M), Elastase Inhibitor IV (10 ⁇ M), ALLN (5 ⁇ M), Antipain (100 ⁇ M). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 6 are graphs showing Control and PMA-activated neutrophil degranulates that were pre-incubated with biotin-VAD-CMK (10 ⁇ M), biotin-FLF-CMK (10 ⁇ M) or Elastase Inhibitor IV (10 ⁇ M) for 30 min on ice followed by incubation with strepavidin agarose beads. Degranulates were subsequently assessed for Cathepsin G activity by FLF-sBzl hydrolysis assay (A) or Elastase activity was assessed by AAPV-AMC hydrolysis.
- HeLa IL36R were stimulated with IL36 ⁇ (A) or IL36 ⁇ (B) pre-incubated for 2 h at 37° with mock, biotin-VAD-CMK (10 ⁇ M) or biotin-FLF-CMK (10 ⁇ M) treated degranulates. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 7 (A) are graphs showing hydrolysis of the synthetic caspase peptide (WEHD-AMC), by caspase-1; the caspase peptide (DEVD-AMC), by caspase-3; the cathepsin peptide (Suc-FLF-sBzL), by purified neutrophil cathepsin G; the elastase peptide (AAPV-AMC), purified neutrophil elastase.
- FIGS. B are graphs showing HeLa IL36R stimulated with 500 pM IL-36 ⁇ , ⁇ and ⁇ pre-incubated for 2 h at 37° with indicated concentrations of recombinant caspase-1,-3 or purified cathepsin-G and elastase.
- IL-1 ⁇ p17 served as a positive control for caspase titrations.
- cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 8 are graphs showing HeLa IL36R stimulated with a titration of IL-36 ⁇ , ⁇ and ⁇ pre-incubated for 2 hr at 37° with fixed concentrations of purified cathepsin-G (50 nM) and elastase (200 nM). After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 9 is a Coomassie blue stained gel of recombinant IL-36 ⁇ that was incubated in the presence or absence of Cathepsin G (50 nM). Indicated fragments were analysed by Edman Degradation sequencing and novel N-termini were identified as ( 6 EAAP) and ( 54 SDKE).
- (B) is schematics representing NPQR 5 and DTEF 53 cleavage motifs within IL-36 ⁇ and point mutants IL-36 ⁇ F53A and IL-36 ⁇ R5A.
- FIG. 10 is a Coomassie blue stained gel of recombinant Recombinant IL-36 ⁇ , IL-36 ⁇ F63A and IL-36 ⁇ R5A were incubated with fixed concentration of cathepsin-G, as indicated, followed by analysis by SDS-PAGE and Coomassie stain. Representative gel is shown from at least two independent experiments.
- FIG. 11 (A) are graphs showing HeLa IL36R SEAP stimulated with a titration of IL36 ⁇ and IL36 ⁇ R5A pre-incubated for 2 h at 37° with cathepsin-G (50 nM). After 24 h, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA.
- B HeLa IL36R stimulated with 500 pM of IL36 ⁇ , IL-36 ⁇ R5A and IL36 ⁇ F53A pre-incubated for 2 h at 37° with a titration of cathepsin-G. After 24 h, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 12 are graphs showing HeLa IL36R stimulated with 500 pM of IL36 ⁇ , IL-36 ⁇ R5A and IL36 ⁇ F53A pre-incubated for 2 h at 37° with a titration of PMA-activated neutrophil degranulate. After 24 hr, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 13 (A) is a Coomassie blue stained gel of recombinant IL-36 ⁇ that was incubated in the presence or absence of Elastase (100 nM). Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as ( 16 YQSM).
- (B) is schematics representing GRAV 16 cleavage motif within IL-36 ⁇ and the point mutant IL-36 ⁇ V15A.
- FIG. 14 (A) is a graph showing recombinant IL-36 ⁇ and IL-36 ⁇ V15A incubated with a titration of Elastase or (B) fixed dose of Elastase (80 nM). After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 15 are graphs showing recombinant IL-36 ⁇ and IL-36 ⁇ V15A incubated with a titration of PMA-activated neutrophil degranulate. After 24 hr, (A) NF-KB activity was measured as a fold iduction of SEAP in the supernatant and (B) cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 16 are graphs showing HaCat stimulated with indicated titration of IL36 ⁇ , ⁇ and ⁇ pre-incubated for 2 h at 37° with cathepsin-G (50 nM), elastase (100 nM). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 17 are graphs showing primary keratinocytes stimulated with indicated titration of IL36 ⁇ , ⁇ and ⁇ pre-incubated for 2 h at 37° with cathepsin-G (50 nM), elastase (100 nM). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 18 are photographs of graphs showing Organotypic skin reconstructs cultivated at the air to liquid interface were topically stimulated with either cathepsin-G alone (We applied 2 ⁇ l in 10 ⁇ l MM), 2 nM IL-36 ⁇ FL or IL-36 ⁇ CatG in a volume of 10 ⁇ l MM, respectively, every other day. Application of 10 ⁇ l MM only served as negative control. After 15 days skin reconstructs were harvested, fixed in paraffin, and sections stained with H&E, against filaggrin, involucrin, cytokeratin 10 and 14 as indicated to display epidermal thickness and differentiation.
- FIG. 19 is a gene expression heat map of IL-36 ⁇ CatG induced in primary keratinocytes at 8 h.
- FIG. 20 are graphs showing primary keratinocytes stimulated with IL-36 ⁇ FL (5 nM) and IL-36 ⁇ CatG (5 nM). At indicated time-points mRNA levels of cytokine were determined by RT-PCR.
- FIG. 21 are graphs showing primary keratinocytes stimulated with IL-36 ⁇ FL (5 nM) and IL-36 ⁇ CatG (5 nM). At indicated time-points levels of cytokine were determined by ELISA.
- C graphs showing primary keratinocytes stimulated with indicated concentrations of recombinant IL-17C. After 48 h, levels of cytokine were determined by ELISA.
- FIG. 22 are immunoblots showing the specificity and cross-reactivity of IL-36 rabbit polyclonal antibodies tested against indicated protein amounts of recombinant IL-36 ligands.
- FIG. 23 (A) are immunoblots showing Primary keratinocytes treated with a titration of IL-36 ⁇ CatG (10, 5, 2.5 nM), PMA (40, 20, 10 nM) and Poly:IC (100, 50, 25 mg/ml). Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot.
- (B) Primary keratinocytes treated with fixed concentrations of IL-36 ⁇ CatG (5 nM), PMA (20 nM) and Poly:IC (100 ⁇ g/ml) over indicated time-points. Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot.
- FIG. 24 (A) are immunoblots showing HaCat treated with a titration of IL-36 ⁇ CatG (10, 5, 2.5 nM), PMA (40, 20, 10 nM) and Poly:IC (100, 50, 25 mg/ml). Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot.
- FIG. 25 are photographs showing primary keratinocytes incubated in the presence or absence of PMA (20 nM) for 12 h, followed by 1 h incubation with SLO (5 ⁇ g/ml).
- (B) is a graph showing primary keratinocytes incubated with indicated concentrations of SLO, followed by transfers of the supernatants onto Hela IL36R cells. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. Cell death is measured by annexin V/PI staining and quantified by flow cytometry. Cells and supernatants were analysed for indicated proteins by immunoblot.
- FIG. 26 (A) is an immunoblot showing endogenous and recombinant IL-36 ⁇ incubated for 1 h at 37° with buffer, elastase (100 nM), cathepsin-G (50 nM), and neutrophil degranulate (1/4 dilution).
- (B) is an immunoblot showing endogenous IL-36 ⁇ incubated for 1 h at 37° with indicated concentrations of elastase, cathepsin-G and neutrophil degranulate.
- FIG. 27 is an immunoblot of control versus psoriatic biopsy samples, analysed for indicated proteins. Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot.
- (B) is an immunoblot showing endogenous IL-36 ⁇ from psoriatic skin incubated for 1 h at 37° in the presence or absence of elastase (100 nM).
- FIG. 28 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 ⁇ M) followed by addition of IL36 ⁇ for 2 h at 37°.
- HeLa IL36R were stimulated for 24 h.
- IL-8 cytokine concentrations in culture supernatants were determined by ELISA. Note: AFLF, GLF peptides and Elast I-IV serve as negative controls for IL-36 ⁇ assay.
- FIG. 29 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 pM) followed by addition of IL36 ⁇ for 2 h at 37°.
- HeLa IL36R were stimulated for 24 h.
- IL-6 cytokine concentrations in culture supernatants were determined by ELISA. Note: Elast I-IV serves as negative controls for IL-36 ⁇ assay.
- FIG. 30 are graphs showing cathepsin-G were pre-incubated for 30 min on ice in the presence or absence of peptide (10 ⁇ M) followed by incubation with IL36 ⁇ .
- HeLa IL36R SEAP were stimulated with samples of each reaction taken at indicated timepoints.
- NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 31 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 pM) followed by addition of IL36 ⁇ for 2 h at 37°.
- HeLa IL36R were stimulated for 24 h.
- IL-6 cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 32 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (200, 100, 50, 25, 12.5 ⁇ M) followed by addition of IL36 ⁇ for 2 h at 37°.
- HeLa IL36R were stimulated for 24 h.
- IL-6 cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 33 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (200, 100, 50, 25, 12.5 ⁇ M) followed by addition of IL36 ⁇ for 2 h at 37°.
- HeLa IL36R were stimulated for 24 h.
- IL-6 cytokine concentrations in culture supernatants were determined by ELISA. Note: AAPV, API, ARPV, DTEF, RPI, RPL, APL, APV, PQR, RAV, and RPV peptides serve as negative controls for IL-36 ⁇ assay.
- FIG. 34 is a Coomassie blue stained gel of recombinant IL-36 ⁇ that was incubated with a titration of purified cathepsin K. Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as ( 6 EAAP).
- (B) is schematics representing NPQR 5 cleavage motif within IL-36 ⁇ and the point mutant IL-36 ⁇ RSA.
- FIG. 35 (A) are graphs showing HeLa IL-36R stimulated with recombinant IL-36 ⁇ and IL-36 ⁇ R5A (625 ⁇ M) incubated with indicated concentrations of cathepsin K. After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 36 is the complete DNA coding sequence (SEQ ID No. 3) and corresponding amino acid sequence (SEQ ID No. 4) for the IL-36 ⁇ gene ( Homo sapiens interleukin 1 family, member 8 (eta), mRNA (cDNA clone MGC:126882 IMAGE:8069339), complete cds)
- FIG. 37 is the complete DNA coding sequence (SEQ ID No. 5) and corresponding amino acid sequence (SEQ ID No. 6) for the IL-36 ⁇ gene ( Homo sapiens interleukin 1 family, member 9, mRNA (cDNA clone MGC:119102 IMAGE:40003612), complete cds)
- FIG. 38 is the complete DNA coding sequence (SEQ ID No. 26) and corresponding amino acid sequence (SEQ ID No. 27) for the IL-36 ⁇ gene ( Homo sapiens interleukin 1 family, member 6, mRNA (cDNA clone MGC:129553 IMAGE:40002576), complete cds)
- FIG. 39 is a Coomassie blue stained gel of recombinant IL-36 ⁇ that was incubated with a titration of purified cathepsin-G and elastase. Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as ( 4 ALKI) for cathepsin-G and ( 5 LKID) elastase, respectively.
- (B) is a schematic representing cathepsin-G and elastase cleavage motifs within IL-36 ⁇ .
- FIG. 40 are graphs showing control and psoriatic skin elutes that were assessed for Cathepsin G activity by FLF-sBzl hydrolysis assay (A) or Elastase activity (B).
- C is a graph showing HeLa IL36R cells incubated with equal concentrations of IL-36 ⁇ , ⁇ , ⁇ cytokines (500 ⁇ M) that had been pre-incubated for 2 h at 37° with either control or psoriatic skin elutes in the presence or absence of either cathepsin G inhibitor 1 (10 ⁇ M) or elastase inhibitor IV (10 ⁇ M).
- IL-8 cytokine concentrations in culture supernatants were determined by ELISA.
- FIG. 41 (A) are graphs showing HeLa IL-36R stimulated with recombinant IL-36 ⁇ and IL-36 ⁇ R5A (500 ⁇ M) incubated with indicated concentrations of proteinase-3 (B) are pM) incubated with indicated concentrations of proteinase-3. After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA.
- Polyclonal antibodies were generated against IL-36 ⁇ , ⁇ and ⁇ by repeated immunization of rabbits with the full-length recombinant IL-36 proteins (Biogenes, Germany).
- anti-IL-1 ⁇ and anti-IL-1 ⁇ were purchased from R&D systems (UK).
- anti-Actin (clone C4) was from MP Biomedicals, anti-Bax (clone 6A7) was from Sigma, anti-Cullin-3 was from BD antibodies.
- biotin-VAD-FMK was purchased from Bachem (Germany); Suc(oMe)-AAPV-AMC (SEQ ID No. 11) was purchased from Peptanova (Germany); biotin-VAD-FMK was purchased from ICN (UK). Novel synthetic peptides biotin-FLF-CMK, z-FLF-CMK, z-AFLF-CMK, z-EPF-CMK, z-GLF-CMK, z-KAL-CMK, z-GLK-CMK and z-GLW-CMK were synthesised by Boston Open Labs (USA).
- Cathepsin G Inhibitor I and Elastase Inhibitor IV were purchased from Calbiochem (UK).
- Purified Neutrophil-derived Cathepsin G was purchased from Calbiochem (UK).
- Purified Neutrophil-derived Elastase was purchased from Serva (Germany). Unless otherwise indicated, all other reagents were purchased from Sigma (Ireland) Ltd.
- Full-length poly-histidine-tagged IL-36 ⁇ , ⁇ and ⁇ proteins was generated by cloning the human coding sequence in frame with the poly-histidine tag sequence in the bacterial expression vector pET45b. Protein was expressed by addition of 600 pM IPTG to exponentially growing cultures of BL21 strain E. coli followed by incubation for 3 h at 37° C. Bacteria were lysed by sonication and poly-histidine tagged proteins were captured using nickel-NTA agarose (Qiagen, UK), followed by elution into PBS, pH 7.2, in the presence of 100 mM imidazole.
- IL-36 Modified forms of IL-36 where cloned that included a caspase-3-processing motif (DEVD) into the IL-36 sequences, N-terminal to the known processing sites 22 . All IL-36 mutants were expressed and purified in the same way. Recombinant poly-histidine-tagged caspases-1, and -3, were also expressed and purified as described above.
- DEVD caspase-3-processing motif
- TCA was added at a 1:4 ratio to supernatant volume (250 ⁇ l to 1 ml supernatant) and incubated on rotation for 10 min. Supernatants were centrifuged at 15,000 g for 10 min. Top layer was removed without disturbing the pellet. 200 ⁇ l pre-chilled acetone was added to each pellet and mixed by several inversions. Samples were centrigued for a further 10 min at 15,000 g. Samples were then put on heating block to burn off the acetone.
- 1 ⁇ SDS-PAGE loading buffer (Tris.Cl, 50 mM, SDS, 2%, Glycerol 10%, Bromophenol Blue, 0.05%, ⁇ -mercaptoethanol, 2.5%) was added to each sample pellet. Samples were then boiled for a further 5 mins. Cell lysates were prepared using SDS-PAGE loading buffer and were electrophoresed on 8-13% SDS-polyacrylamide gels followed by transfer onto nitrocellulose membranes. Protein expression was subsequently examined by immunoblotting with the appropriate antibodies.
- neutrophils Primary neutrophils were purified from donor human blood using the plasma-Percoll gradient method. Purity of cell preparations (>90%) was determined by Hematoxylin and Eosin staining of cytospins. To prepare degranulates, neutrophils (10 7 per treatment) were stimulated in the presence or absence of 50 nM PMA in HBSS/0.25% BSA for 1-3 h at 37° C. in a humidified atmosphere with 5% CO 2 . Supernatants were harvested and clarified by centrifugation. Degranulate aliquots were stored at ⁇ 80°.
- Reactions (50 ⁇ l final volume) were carried out in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS/2 mM DTT) containing 50 pM Ac-DEVD-AFC, Ac-WEND-AMC, Suc(oMe)-AAPV-AMC. Samples were measured by using an automated fluorimeter (Spectrafluor Plus; TECAN) at wavelengths of 430 nm (excitation) and 535 nm (emission).
- protease reaction buffer 50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS/2 mM DTT
- Samples were measured by using an automated fluorimeter (Spectrafluor Plus; TECAN) at wavelengths of 430 nm (excitation) and 535 nm (emission).
- substrate was diluted to a final concentration of 300 pM in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS/DTNB 300 ⁇ M). Samples were measured by automated fluorimeter (Spectrafluor Plus; TECAN) at an absorbance wavelength of 430 nM.
- Cytokines and chemokines were measured from cell culture supernatants using specific ELISA kits obtained from R&D systems (human IL-6, IL-8, CXCL1, MCP-1, IL-17C). Each assay was repeated a minimum of three times and all cytokine assays were carried out using triplicate samples from each culture.
- HeLa were cultured in RPMI media (Gibco), supplemented with 5% fetal calf serum (FCS).
- HaCat were cultured in DMEM (Gibco) supplemented with FCS (10%).
- Primary neonatal foreskin derived Keratinocytes P0 were purchased from Cell Systems (Germany) and cultured in serum-free Dermalife K media (Cell Systems, Germany).
- HeLa.vector or HeLa.IL-36R cell lines were generated by transfection with pCDNA3 or pCDNA3.IL-1rrp2 followed by selection using G-418 antibiotic (Sigma).
- IL-1rrp2 over-expressing clones were confirmed by immunoblotting and the final clone selected by demonstration of acquired responsiveness to active forms of IL-36. All cells were cultured at 37° C. in a humidified atmosphere with 5% CO 2 .
- Sections were released from paraffin using Roticlear (Roth) and subjected to HE-staining at RT or were incubated with primary antibodies against keratin 10 (Dako, Hamburg, Germany), keratin 14, filaggrin (Biomedia, Singapore) and involucrin (Acris, Herford, Germany), respectively, as recommended by the manufacturer at 4° C. over night.
- Roticlear Roticlear
- P3 Primary human neonatal foreskin-derived Keratinocytes (P3) were used for gene expression analysis. Primary Keratinocytes were stimulated with IL-36 ⁇ for 8 and 24 h timepoints. Cells were harvested with RNAprotect cell reagent (Qiagen) and stored at ⁇ 80°. Analysis of samples were performed using SurePrint G3 Human Gene Expression 8x60K v2 Microarray using a one-color based hybridization protocol and preformed by IMGM Laboratories (Germany).
- RNA Analysis by Real-Time PCR RT-PCR
- IL-17C Forward (SEQ ID No. 12) 5′ TTG GAG GCA GAC ACC CAC C 3′
- IL-17C Reverse (SEQ ID No. 13) 5′ GAT AGC GGT CCT CAT CCG TG 3′ IL-36 ⁇ Forward
- SEQ ID No. 14 5′ GAA ACC CTT CCT TTT CTA CCG TG 3′ IL-36 ⁇ Reverse (SEQ ID No. 15) 5′ GCT GGT CTC TCT TGG AGG AG 3′ IL-8 Forward (SEQ ID No.
- Fixomull (2 cm ⁇ 2 cm) adhesive tape strips were applied to a healthy or psoriatic skin, under firm pressue for 10 seconds.
- the tape-strip was placed in sterile 1.5 ml eppendorfs and eluated with protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS) under constant rotation for 1 h at 4° c.
- Sample eluates were stored at ⁇ 80° C. Enzymatic assays and bioassays were setup using control and psoriatic eluates as described above.
- IL-36 is incubated with the protease for approximately 2 hours at 37° C. The reaction is then added to a cell line and the biological activity of the IL-36 protein is determined by the ability of IL-36 receptor (IL-36R) expressing cells, such as HeLa cells, Primary Keratinocytes, HaCat cells, to secrete factors into the cell culture medium. These secreted factors are quantified by ELISA (as shown in for example, FIG. 4B , FIG. 7 , FIG. 8 , FIG. 16 , FIG. 17 , FIG. 21A ).
- IL-36R IL-36 receptor
- the protease is incubated with IL-36 for approximately 2 hours at 37° C., and the resulting reaction is analyzed by gel electrophoresis using an SDS-PAGE gel to separate denatured protein by the length of the polypeptide.
- the SDS-PAGE gel is then transferred onto PDVF membrane. This embeds the protein content of the SDS-PAGE gel onto the PVDF membrane.
- the PDVF membrane is stained with Coomassie blue. This dye stains the protein content of the PDVF and resolves the IL-36 protein and any cleavage bands are also made visible.
- cleavage bands are subsequently excised and analysed by conventional Edman degradation sequencing to determine what is the N-terminus amino acid for the particular cleavage band that has been analysed. This is shown in, for example, IL-36 ⁇ (see FIG. 39 ), IL-36 ⁇ (see FIG. 9-12 , FIG. 34 ) and IL-36 ⁇ (see FIG. 13-15 ).
- peptides including tri-/tetra-peptides, can be designed that mimic these cleavage motifs using conventional techniques.
- a tri-/tetra-peptide will encompass the residues upstream and downstream of the cleavage site.
- the general nomenclature of cleavage site positions of the substrate were formulated by Schechter and Berger 32-33 . They designate the cleavage site between P1-P1′, incrementing the numbering in the N-terminal direction of the cleaved peptide bond (P2, P3, P4, etc.). On the carboxyl side of the cleavage site the numbering is incremented in the same way (P1′, P2′, P3′ etc.).
- RAV peptide ( FIG. 32 , second row) mimics the cleavage site of IL-36 ⁇ GRAV 15 , (G-R-A-V-P1′-P2′-P3′).
- KAL peptide ( FIG. 28 , second row) mimics the cleavage site of IL-36 ⁇ MEK 3 AL, (M-E-K-P1′-P2′-P3′) by cathepsin-G and the cleavage site of IL-36c(MEKA 4 L, (M-E-K-A-P1′-P2′-P3′) by elastase.
- peptides including tri-/tetra-peptides, can be designed that bind these proteases using conventional techniques.
- Nicholson et al. (Nicholson D W, Ali A, Thornberry N A, Vaillancourt J P, Ding C K, Gallant M, Gareau Y, Griffin P R, Labelle M, Lazebnik Y A, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43)).
- an amino acid with both ⁇ -amino group and side chain protection is immobilized to a resin.
- the ⁇ -amino-protecting group is usually an acid-sensitive tert-butoxycarbonyl (Boc) group or a base-sensitive 9-fluorenylmethyloxycarbonyl (Fmoc) group.
- Boc acid-sensitive tert-butoxycarbonyl
- Fmoc base-sensitive 9-fluorenylmethyloxycarbonyl
- CMK chloromethyl ketone
- the CMK chemical group located at the C-terminus of the peptide will occupy the active site but will form a covalent bond resulting in irreversible inhibition of the protease. More specifically, CMK are transition-state irreversible inhibitors.
- the active site Ser 195 of the enzyme forms a tetrahedral adduct with the carbonyl group of the inhibitor, and the active site histidine is alkylated by the CMK functional group (See REF:35)
- IL-36 bioassay To identify the proteases responsible for processing and activation of IL-36 cytokines, we established an IL-36 bioassay by stably transfecting HeLa cells with the human IL-36 receptor (IL-1 Rrp2). Sims and colleagues have reported that artificial truncation of IL-36 ⁇ , ⁇ and ⁇ at particular N-terminal residues dramatically increases the activity of these proteins 24 ( FIG. 1 a ). To confirm that HeLa IL-36R cells were IL-36-responsive, we created modified forms of IL-36 ⁇ , ⁇ and ⁇ by inserting a caspase-3 cleavage motif, DEVD, proximal to the residues identified by Towne et al.
- DEVD caspase-3 cleavage motif
- FIG. 1 a illustrates, DEVD-modified IL-36 ⁇ (IL-36b DEVD ) and DEVD-modified IL-36 ⁇ (IL-36g DEVD ) was readily processed by caspase-3 whereas IL-36b wt and IL-36g wt were not.
- HeLa wt cells failed to respond to either full length or caspase-3-cleaved IL-36 ⁇ DEVD , while HeLa IL-36R cells secreted multiple cytokines in response to caspase-3-processed IL-36 ⁇ DEVD but not full length unprocessed IL-36 ⁇ DEVD ( FIG. 2 a, b , FIG. 3 ). Similar data were obtained for a DEVD-modified form of IL-36 ⁇ ( FIG. 3 a, b ). Furthermore, the transformed skin line HaCat, which naturally express IL-1Rrp2, also responded to the caspase-3-cleaved IL-36 DEVD forms. ( FIG. 3 d ). These data confirmed that proteolytic processing of IL-36 ⁇ , ⁇ and ⁇ dramatically increase the biological activity of these cytokines and established a bioassay to screen for proteases that naturally process and activate IL-36 cytokines.
- Neutrophil granule proteases contain three major seine proteases (elastase, cathepsin G and proteinase-3) that are involved in bacterial killing as well as in the processing of certain cytokines and chemokines 27 . Indeed, previous studies have found that neutrophil elastase can process and activate IL-1 ⁇ 28 and that cathepsin G and elastase can activate IL-33 29 .
- FIG. 5 illustrates the serine protease inhibitor PMSF, as well a specific chemical inhibitor of cathepsin G robustly inhibited the activation of IL-36 ⁇ and IL-36 ⁇ while a specific chemical inhibitor of elastase inhibited the activation of IL-36 ⁇ by activated neutrophil degranulates.
- a panel of peptides based upon optimal cathepsin G cleavage motifs.
- FIG. 6 the cathepsin G-inhibitory peptides, FLF-CMK, AFLF-CMK and EPF-CMK, proved to be the most potent inhibitors of IL-36 ⁇ activation by neutrophil degranulates.
- IL-36 ⁇ activation was antagonized by a specific chemical inhibitor of elastase ( FIG. 6 ).
- FIG. 6 a illustrates, selective depletion of cathepsin G activity from PMA-treated neutrophil degranulates using biotin-FLF-CMK largely eliminated activation of IL-36b but not of IL-36g ( FIG. 6 b ).
- FIG. 7 a The activity of all purified proteases employed was confirmed using synthetic substrate peptides.
- FIG. 7 b demonstrates, cathepsin G selectively promoted IL-36 ⁇ activation, whereas elastase and proteinase-3 preferentially activated IL-36 ⁇ .
- IL-36 ⁇ is activated by cathepsin-G and proteinase-3 ( FIG. 7 b ).
- caspase-1 processes and activates the IL-1 family cytokines, IL-1 ⁇ and IL-18
- caspase-1 or caspase-3 could process and activate IL-36 family cytokines.
- FIG. 7 b illustrates, neither caspase activated any of the IL-36 cytokines.
- concentrations of IL-36 ⁇ we used in the above experiments were too low to detect biological activity, we also titrated IL-36 cytokines over a wide concentration range in the presence and absence of cathepsin G, elastase or proteinase-3. As FIG.
- IL-36 ⁇ F53A suppresses appearance of the two major cleavage bands ( ⁇ 10 and ⁇ 4 kDa), yet still generates a third cleavage band ( ⁇ 17 kDa) just below the full-length protein.
- IL-36 ⁇ R5A largely attenuates the appearance of the ⁇ 17 kDa band just below the full-length band while the appearance of the cleavage bands ( ⁇ 10 and ⁇ 4 kDa) are significantly diminished.
- FIG. 11 FIG. 12 illustrate, whereas mutation of Phe53 had no effect on cathepsin G-mediated IL-36 ⁇ activation, mutation of Arg5 dramatically abolished activation of this cytokine.
- Activated IL-36 Promotes Robust Cytokine Production by Keratinocytes
- cathepsin G-processed IL-36 ⁇ was sufficient to perturb skin differentiation to produce features resembling psoriasis, such as acanthosis and marked hyperkeratosis of the cornified layer ( FIG. 18 ).
- IL-36b is Sufficient to Drive IL-17 Production in Keratinocytes
- IL-36 induced robust expression of a diverse array of pro-inflammatory cytokines and chemokines from these cells.
- IL-36 induced strong transcriptional upregulation of IL-17C ( ⁇ 50-fold within 8 hours), a cytokine that has been implicated as a key driver of the pathology observed in psoriasis and other conditions.
- IL-36 ⁇ also induced robust expression of multiple additional inflammatory factors, such as complement C3, b-defensin-2, S100A9, TNF ⁇ , and G-CSF which are frequently elevated in lesional skin from psoriatic patients 19 ( FIG. 19 ).
- IL-36 ⁇ induced a strong signature of IL-36 ⁇ upregulation in primary keratinocytes, suggesting that this cytokine can promote a positive feedback loop for IL-36 cytokine expression.
- IL-17C can itself promote cytokine production from primary keratinocytes ( FIG. 21 c ).
- FIG. 22 To explore the expression of endogenous IL-36 cytokines in keratinocytes, we generated polyclonal antibodies against all three IL-36 cytokines ( FIG. 22 ). Whereas little endogenous IL-36 ⁇ or ⁇ could be detected constitutively, IL-36 ⁇ was detected in primary keratinocytes ( FIG. 22 a ). However, treatment of these cells with IL-36, PMA or the Toll-3 agonist poly:(IC) robustly induced the expression of endogenous IL-36 ⁇ ( FIG. 23 a, b ). HaCat were also found to upregulate IL-36 ⁇ after IL-36 and PMA treatment ( FIG. 24 a, b ).
- FIG. 26 a, b illustrates, IL-36 ⁇ incubated with elastase resulted in robust IL-36 ⁇ proteolysis both intracellularly as well as extracellularly, with the resulting cleavage fragments running at a similar mobility to that produced through proteolysis of recombinant IL-36 ⁇ by elastase.
- IL-36 ⁇ is Greatly Elevated within Lesional Skin from Psoriatic Individuals
- IL-36 ⁇ was robustly activated by psoriatic skin eluates, with IL-36 ⁇ activated but to much less efficient degree. Control skin eluates failed to activate IL-36 cytokines. Consistent with the cathepsin-G-like enzymatic activity, a specific cathepsin-G inhibitor attenuated IL-36 ⁇ and IL-36 ⁇ activation by the psoriatic skin eluates, while an elastase inhibitor failed to attenuate IL-36 activation. These data, are consistent with a cathepsin-G like enzymatic activity in psoriatic skin that is capable of activating IL-36 ⁇ .
- IL-36 cytokines are activated by neutrophil granule proteases.
- IL-36 ⁇ and IL36 ⁇ are processed by cathepsin G,elastase and proteinase-3, respectively and proteolysis of these cytokines releases their full biological potency.
- Previous reports by Sims and colleagues 24 suggested that IL-36 cytokines have limited biological activity as full-length proteins, and require processing at their N-termini to activate them.
- the latter authors did not identify the proteases that naturally process and activate these cytokines, but mapped their active forms using artificial truncations.
- IL-36 cytokines have very limited biological activity as full-length proteins, however proteolysis by cathepsin G,elastase and proteinase-3 greatly enhanced the biological activity of IL-36 ⁇ and IL-36 ⁇ respectively.
- IL-36 cytokines may induce a profound conformational change in these proteins that increase their affinity for the IL-36 receptor (IL-1 Rrp2), thereby increasing biological potency.
- the IL-36 N-termini may partly occlude the receptor binding domain, removal of which permits a more stable interaction with the IL-36R complex.
- Hazuda and colleagues have reported that pro-IL-1 ⁇ and pro-IL-1 ⁇ cytokines undergo profound conformational changes upon removal of their N-termini and, as a consequence, the mature regions of these molecules switch from a proteinase K-sensitive to a proteinase K-insensitive state. This change is most likely reflected in an altered conformation that increase their affinity for the IL-1 receptor 26 .
- Immune cell infiltration is a hallmark of a number of skin-related inflammatory diseases.
- psoriatic plaques are heavily infiltrated with neutrophils, dendritic cells, macrophages, and T-cells 26 .
- Neutrophils are critical first responder cells in our innate immune system and play a critical role in the initial response to infection or tissue damage.
- Neutrophils perform a range of functions in their role in immune defence and inflammation which includes: engulfment and destruction of microbes via ROS production, release of neutrophil extracellular traps to sequester and kill microbes, release of cytokines to orchestrate immune responses, as well as the production of a vast repertoire of antimicrobial molecules such as defensins, and granule proteases such as elastase and cathepsin G 27 . Furthermore, mice doubly deficient in the neutrophil granule proteases cathepsin G and elastase have deficiencies in bacterial clearance as well as increased mortality to streptococcus, pseudomonas , and mycobacterial infections 28-28 .
- neutrophil proteases While the degranulation and release of neutrophil proteases exert profound antimicrobial and protective effects during infection, in excess they can cause extensive tissue damage through ROS production, inflammatory cytokine activation, as described herein, and protease degradation of the extracellular matrix 31 . Excessive neutrophil protease activity is typically prevented by serum anti-proteases such as ⁇ -1-antitrypsin and 2-macroglobulin that are also typically synthesized during inflammatory responses 27 .
- serum anti-proteases such as ⁇ -1-antitrypsin and 2-macroglobulin
- necrosis is not a direct consequence of pathogen activities, necrosis of barrier tissues as a result of compression injuries or burns, for example, is likely to lead to infection.
- the immune system recognizes this as potential danger and mounts an innate immune response characterized by the infiltration immune cells such as neutrophils and macrophages into the site of injury 9,30 .
- Necrosis can also lead to robust activation and infiltration of the injured site by cells of the immune systems such as neutrophils, macrophages and mast cells. It is under these conditions that extracellular IL-36 ligands may encounter and become processed by neutrophil serine proteases as these proteases are frequently found at elevated levels within psoriatic lesions. Indeed, our results show that activated IL-36 is capable of driving a robust inflammatory response in primary keratinocytes, including the induction of IL-1 ⁇ , TNF ⁇ , IL-17C, G-CSF, IL-8, S100 proteins, as well as IL-36 itself. Keratinocytes make up the majority of cells within the epidermis, which constitutes a very important barrier against infection.
- keratinocytes are capable of directly responding to damage or infection by releasing a number of key cytokines, such as IL-1 ⁇ , IL-1 ⁇ and IL-36 cytokines to activate local macrophages and dendritic cells to initiate immune responses 5 .
- cytokines such as IL-1 ⁇ , IL-1 ⁇ and IL-36 cytokines to activate local macrophages and dendritic cells to initiate immune responses 5 .
- keratinocytes serve as key sentinel cells that alert the immune system to potential danger.
- IL-36 ⁇ as well as IL-1 ⁇ / ⁇ , are endogenously expressed by keratinocytes and subject to modulation by either IL-36 signalling or Toll-receptor engagement.
- keratinocytes are posed to release cytokines such as IL-36 ⁇ and IL-1 ⁇ upon tissue injury.
- cytokines such as IL-36 ⁇ and IL-1 ⁇ upon tissue injury.
- damage to keratinocytes is likely to play an important initiating role in psoriasis, especially in individuals carrying genetic predispositions to this disease (such as deficiency in the IL-36R antagonist).
- IL-36 cytokines are robustly activated by the neutrophil proteases, cathepsin G,elastase and proteinase-3, as well as cathepsin K, and that this proteolysis increases their biological activity ⁇ 500-fold.
- neutrophil proteases as potent activators of IL-36 cytokines and suggest that targeted inhibition of these proteases, as described here, may have therapeutic benefits in inflammatory skin conditions such as psoriasis and other similar conditions.
Abstract
Description
- This application is a divisional application of U.S. application Ser. No. 15/512,139, filed 17 Mar. 2017, which is a National Stage entry of International Application No. PCT/EP2015/071446, filed 18 Sep. 2015, which claims priority to European Patent Application No. 14185397.8, filed 18 Sep. 2014.
- Pursuant to the EFS-Web legal framework and 37 CFR §§ 1.821-825 (see MPEP § 2442.03(a)), a Sequence Listing in the form of an ASCII-compliant text file (entitled “Sequence_Listing_3000036-002001_ST25.txt” created on 12 Aug. 2020, and 12,153 bytes in size) is submitted concurrently with the instant application, and the entire contents of the Sequence Listing are incorporated herein by reference.
- This invention relates to the use of an agent capable of inhibiting interleukin-36 (IL-36) proteolytic processing for the treatment and/or reduction of inflammation in a subject. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.
- Inflammation of barrier organs, including the gut, lung and skin can result in many undesirable chronic long term conditions including inflammatory skin conditions, inflammatory bowel disease and associated conditions of Crohn's disease, ulcerative colitis, and colorectal cancer and chronic obstructive pulmonary disease. These conditions tend to be difficult to treat and costly from both a long-term management and healthcare perspective. New ways of effectively treating these chronic and long-term conditions are of great importance.
- Inflammation of barrier organs in a subject includes inflammation of the skin, gut and/or lung. For example, inflammatory skin conditions typically present as heterogenous conditions with disease subtypes displaying varying degrees of severity, from mild itching to grave medical health complications. They are characterized by irritation and excessive inflammation of the skin. These diseases may sometimes be disfiguring and can cause great discomfort to the affected individual. Inflammatory skin conditions include psoriasis such as plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, palmoplanter pustulosis, psoriatic nail disease, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis, acne and ichthyosis vulgaris.
- What underpins this heterogeneity is not clear in many cases but some inflammatory conditions have a clear genetic component that predisposes particular individuals to spontaneous autoinflammatory disease or exacerbates immune reactions to infectious agents1-2. In severe cases, such as in mongenic autoinflammatory disease, the genetic perturbation can be mapped to loss-of-function or severe hypomorphic mutations in single genes, such as NLPR3 in cryopyrin-associated periodic syndromes (CAPS), deficiency in IL-1R antagonist (DIRA) and Deficiency in IL-36R antagonist (DITRA)1-2. In both of the latter examples, there is extreme hypersensitivity to disturbance of the skin barrier, the first line of defence against injury or infection. As a consequence, such individuals frequently display severe and life threatening autoinflammatory diseases such as generalized pustular psoriasis, pustulosis or stomatitis1. The underlying genetic basis of elevated pro-inflammatory responses in other immune diseases are somewhat less obvious and typically includes deregulation of multiple inflammatory pathways and environmental components, but nonetheless leads to heightened and prolonged immune responses that lead to conditions such as psoriasis, dermatitis, inflammatory bowel diseases and rheumatoid arthritis. However, it is becoming increasingly clear that particular cytokines, such as members of the extended IL-1 family and TNF, play central roles in initiating and/or sustaining many of these autoimmune/autoinflammatory conditions.
- Psoriasis is a common inflammatory skin condition that effects approximately 1-3% of the Caucasian population3. The most prevalent form of this condition, plaque psoriasis, accounts for approximately 80% of cases. Of those, the related, psoriatic arthritis is encountered in 5-30% of individuals. Palmoplanter psoriasis is encountered in about 10% of psoriasis patients and a life-threatening severe form of psoriasis, Generalized Pustular Psoriasis (GPP), accounts for less than 5% of cases3. Psoriasis is characterised by hyperproliferation and impaired differentiation of keratinocytes, the most abundant cell type in the skin, leading to thickening of the skin in lesional areas (acanthosis). It is well established that psoriasis features excessive inflammatory reactions in the skin, as a result of innate as well as adaptive immune cell types that result in the pathological features of psoriasis. While the triggering events remain unclear, skin damage, viral and bacterial infection (e.g streptococcal bacteria in the throat) and inherited genetic susceptibilities are all major factors4-5.
- Current treatment for psoriasis include the use of agents such as anthralin (dihydroxyanthralin), azarabine, colchicine, fluorouracil, methotrexate, methoxsalen (8-methoxypsoralen), resorcinol, retinoids (for example, retinoic acid), corticosteroids (for example, clobetasol propionate, trimcinolone acetonide and the like), cyclosporin, iodochlorhydroxyquin, salicyclic acid, vitamin D, dapsone, somatostatin, sulfur, tars and zinc oxide. Ultra-violet light treatment, alone or in combination with other agents such as psoralen (i.e., PUVA treatment), is also used to treat psoriasis3. Because of the critical role that cytokines play in driving inflammation, and by extension the pathological effects associated with excessive inflammation, apical cytokines and their downstream effectors represent very attractive therapeutic targets. Cytokine-targeted biologics are highly specific with minimal off-target effects or toxicity. As a consequence, there has been a revolution in the development of cytokine-targeted biological therapies using neutralizing antibodies or receptor-IgFc fusion proteins over the past decade. In particular, TNF neutralization has been transformative in the treatment of several inflammatory diseases6-7, and neutralization approaches targeted against IL-12/IL-23, IL-17, and IL-4 have entered the clinic or are on clinical trials at present. In particular, IL-12/IL-23 and IL-17 neutralizing antibodies have shown great efficacy in the treatment of moderate to severe forms (>10% surface area affected) of psoriasis during clinical trials8.
- IL-1 family cytokines, which include the recently described IL-36α, β and γ proteins, play major roles as initiators of inflammation and are frequently among the first cytokines produced in response to infection or injury8-11. IL-1 cytokines are capable of triggering complex cascades of additional cytokine production from diverse cells types, such as resident tissue macrophages and dendritic cells, as well as keratinocytes and endothelial cells lining local blood vessels12-14. IL-36α, IL-361β and IL-36γ are encoded by distinct genes and evidence is rapidly accumulating to suggest that these cytokines play a key role in skin inflammation, particularly in psoriasis15.
- Individuals that carry hypomorphic mutations in the IL-36 receptor antagonist (IL-36RA) display a severe and highly debilitating form of psoriasis, called generalized pustular psoriasis1,16-18. This suggests that deregulated IL-36 cytokine signaling is sufficient to drive aggressive skin inflammation and also that IL-36 is an important barrier cytokine. Moreover, analysis of IL-36 mRNA expression in skin biopsies from individuals with the most common form of psoriasis, psoriasis vulgaris, found dramatically elevated expression (100-fold) of all three IL-36 transcripts compared with non-lesional skin from the same individuals, or non-affected controls19. Consistent with the idea that elevated IL-36 activity is an initiating event in psoriasis, transgenic expression of IL-36α in the mouse leads to a psoriasis-like condition at birth that can be further exacerbated with the skin irritant, phorbol acetate20-21. Application of a toll receptor agonist (imiquomod) to the skin in humans and mice can provoke psoriasis outbreaks23, which are increased in severity in IL-36RA−/− mice22. Furthermore, imiquomod-induced psoriasis in mouse models is completely abolished on an IL-36R−/− background22, and transplantation of human psoriatic lesions onto immunodeficient (SCID) mice produces a psoriasis-like condition that is greatly improved through blocking the IL-36 receptor20.
- IL-36α, IL-361β and IL-36γ are all generated as leaderless cytokines that lack biological activity24. Thus, proteolytic processing of IL-36 proteins is required to unlock the pro-inflammatory potential of these cytokines, similar to other members of the IL-1 family, such as IL-1β and IL-18. Sims and colleagues24 have shown that removal of a small number of residues from the N-termini of IL-36α, IL-368 and IL-36γ increases their biological activity by greater than 10,000-fold. Because IL-36 cytokines appear to play a key role as initiators of inflammation in the skin barrier, inhibitors of IL-36 activation are therefore likely to have considerable potential for the treatment of inflammatory skin conditions15.
- However, to date there are no specific compositions or treatment methods which address and target the IL-36 aspect of inflammatory disorders. Accordingly, the present invention is directed to new and improved methods and compositions for the treatment of inflammatory conditions.
- According to a first aspect of the invention, there is provided the use of an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, for the treatment and/or reduction of inflammation, particularly inflammatory skin disorders, in a subject.
- According to a second aspect of the invention, there is provided a composition comprising an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, and a suitable pharmaceutical excipient.
- According to a third aspect of the invention, there is provided a topical inflammatory skin disorder treatment composition comprising an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, and a suitable pharmaceutical excipient.
- According to a forth aspect of the invention, there is provided an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, for use in the manufacture of a medicament for the treatment and/or reduction of inflammation particularly inflammatory skin disorders, in a subject.
- According to a fifth aspect of the invention, there is provided a method for the treatment and/or reduction of inflammation in a subject, preferably inflammation of barrier organs, including inflammation of the skin, gut and/or lung, particularly inflammatory skin disorders, comprising administering an agent capable of inhibiting IL-36 proteolytic processing, particularly IL-36 activation that occurs via proteolytic processing, to a subject to result in the treatment and/or reduction of inflammation in said subject.
- Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those skilled in the art to. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference; thus, the inclusion of such definitions herein should not be construed to represent a substantial difference over what is generally understood in the art.
- In particular, the terms “physiologically acceptable excipient” or “pharmaceutically acceptable excipient” herein refers to a substance devoid of any pharmacological effect of its own and which does not produce adverse reactions when administered to a mammal, preferably a human. Physiologically acceptable excipients are well known in the art and are disclosed, for instance in the Handbook of Pharmaceutical Excipients, sixth edition (2009), herein incorporated by reference.
- The term “approximately” herein refers to the range of the experimental error, which may occur in a measurement.
- The terms “comprising”, “having”, “including” and “containing” are to be construed as open-ended terms (i.e. meaning “including, but not limited to”) and are to be considered as including the terms as “consist essentially of”, “consisting essentially of”, “consist of” or “consisting of”.
- The terms “consist essentially of”, “consisting essentially of” are to be construed as a semi-closed terms, meaning that no other ingredients which materially affects the basic and novel characteristics of the invention are included (optional excipients may thus be included).
- The terms “consists of”, “consisting of” are to be construed as a closed term. As used herein, the terms “therapeutically effective amount” and “effective amount” refer to an amount sufficient to elicit the desired biological response. In the present invention the desired biological response is to inhibit, reduce or ameliorate the severity, duration, progression, or onset of inflammation or associated disease, disorder or condition, prevent the advancement, recurrence, or progression of inflammation or associated disease, disorder or condition or a symptom associated with a disease, disorder or condition. The precise amount of compound administered to a subject will depend on the mode of administration, the type and severity of the disease, disorder or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound described herein being used. In cases where no amount is expressly noted, an effective amount should be assumed.
- As used herein, the terms “treat”, “treatment” and “treating” refer to therapeutic treatments includes the reduction or amelioration of the progression, severity and/or duration of inflammation of associated disease, disorder or condition, or the amelioration of one or more symptoms (specifically, one or more discernible symptoms) of inflammation or associated disease, disorder or condition, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a compound or composition of the invention). In specific embodiments, the therapeutic treatment includes the amelioration of at least one measurable physical parameter of inflammation or associated disease, disorder or condition. In other embodiments the therapeutic treatment includes the inhibition of the progression of inflammation or associated condition, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the therapeutic treatment includes the reduction or stabilization of inflammation or associated disease, disorder or condition.
- As used herein, the terms “subject” and “patient” are used interchangeably. The terms “subject” and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), specifically a “mammal” including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more specifically a human. In one embodiment, the subject is a human.
- In this specification, it will be understood that reference to Interleukin-36, IL-36 cytokines or IL-36 includes one or more of the IL-36 isoforms, IL-36α (IL-36A; IL-36 alpha; Interleukin-36 alpha), IL-36β (IL-36B;IL-36 beta; Interleukin-36 beta) and/or IL-36γ (IL-36G;IL-36 gamma; Interleukin-36 gamma) and reference to IL-36 proteolytic processing includes one or more of IL-36α, IL-36β and/or IL-36γ proteolytic processing.
- In this specification, it will be understood that reference to protease cleavage site or relevant protease cleavage site refers to an IL-36 protease cleavage site which is required for activation of IL-36.
- According to a first aspect of the invention, there is provided the use of an agent capable of inhibiting IL-36 activation that occurs via proteolytic processing for the treatment and/or reduction of inflammation in a subject. Although, the treatment and/or reduction of inflammation of the skin, gut and/or lung is contemplated, the treatment and/or reduction of inflammatory skin disorders are preferred.
- The agent of the invention prevents the production of a biologically active IL-36 by preventing the activation that occurs by proteolytic processing of IL-36, including one or more of IL-36α, IL-36β and/or IL-36γ, to prevent and/or reduce the pro-inflammatory effects of IL-36 including IL-36α, IL-36β and/or IL-36γ. Previously, it was not known which proteases were responsible for activation of IL-36 proteins. We have surprisingly discovered that the neutrophil-derived proteases, including serine proteases and cysteine proteases such as cathepsin G and elastase are potent IL-36, IL-36α, IL-36β (IL-36B) and/or IL-36γ (IL-36G), processing proteases. Other relevant proteases which may be targeted in the invention include cathepsin K, proteinase-3 and/or DPPI (dipeptidyl peptidase I) known as Cathepsin C. As psoriasis plaques are frequently associated with neutrophil infiltrates, we have surprisingly found that inhibitors of neutrophil granule proteases have significant potential as inhibitors of IL-36 activation in inflammatory skin conditions, including but not limited to psoriasis. These surprising findings suggest that targeted inhibition of these proteases have therapeutic benefits in inflammatory skin conditions such as psoriasis and other similar skin conditions.
- We have also identified the protease cleavage sites within the IL-36 isoforms which result in the activation of IL-36. Our findings suggest that the protease cleavage sites of the IL-36 isoforms may also be targeted and/or mimicked to directly inhibit IL-36 activation.
- We postulate that the prevention of a biologically active IL-36 isoform can be used in the treatment and/or prevention of IL-36 associated diseases or disorders.
- It will be understood that the agent of the invention may inhibit IL-36 proteolytic processing either directly or indirectly. Direct inhibition aims to target and/or mimic the newly identified IL-36 protease cleavage sites and/or amino acid residues downstream and/or upstream of the cleavage site. Indirect inhibition aims to inhibit the activity of the IL-36 activating proteases and activators thereof. According to a preferred embodiment of the invention, the agent inhibits IL-36 activation by binding to the IL-36 protease cleavage sites required for activation of IL-36 (direct inhibition) and/or amino acid residues downstream and/or upstream of the cleavage site; and/or the agent prevents and/or inhibits the activity of IL-36 activating proteases or activators thereof (indirect inhibition).
- The agent may be selected from one or more of the following group a small molecule or biologics, including peptide, polypeptide, protein, siRNA, sgRNA, and antibody.
- According to a preferred embodiment, the agent is a small molecule protease inhibitor. According to a preferred embodiment the small molecule protease inhibitor is a serine protease or cysteine protease inhibitor. For example, the protease inhibitor may be selected from one or more of a cathepsin K inhibitor, cathepsin C(DPPI) inhibitor, elastase inhibitor, cathepsin-G inhibitor and proteinase-3 inhibitor. Suitable protease inhibitors, include, but are not limited to boswellic Acids, cathepsin G inhibitor I, Elastase inhibitor IV, Sodium Fluoride, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF⋅HCl), phenylmethanesulfonylfluoride (PMSF), Odanacatib™ (MK-0822) (N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide), Balicatib™ (N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide), MV061194, Aprotinin™ (small protein bovine pancreatic trypsin inhibitor (BPTI)), Leupeptin™ (N-Acetyl-leucyl-N-{(5-[(diaminomethylidene)amino]-1-oxopentan-2-yl}-leucinamide), peptide inhibitor dipeptide-derived diazoketones such as Gly-Phe-CHN2 and vinyl sulfones such as Ala-Hph-VS-Ph.
- Optional protease inhibitors includes aspartate protease inhibitors, glutamic acid protease inhibitors, metalloprotease inhibitors, asparagine peptide lyase inhibitors.
- According to another preferred embodiment, the agent is a peptide, derivative, peptidomimetic or combination thereof. Ideally, the peptide comprises 3, 4, 5, 6,7, 8, 9 or 10 amino acids. In one preferred embodiment, the peptide is a tripeptide or tetrapeptide. The peptide is a synthetic or non-natural peptide. The peptide may inhibit IL-36 activation via proteolytic processing in several ways including:
-
- i) by binding to the protease cleavage site(s) within IL-36 required for activation of IL-36;
- ii) competing with IL-36 activating protease(s) for binding to the protease cleavage site(s) within IL-36 required for activation of IL-36; and/or
- iii) inhibiting IL-36 activation by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof;
- Suitable peptides include Lys-Ala-Leu (KAL); Ala-Leu-Ala (ALA); Met-Ala-Leu-Ala (MALA); Asp-Pro Gln-Arg (NPQR); Pro-Gln-Arg (PQR); Gln-Arg-Glu-Ala (QREA); Arg-Ala-Val (RAV); Gly-Arg-Ala-Val (GRAV); Ala-Val-Tyr-Gln (AVYQ); and derivatives or peptidomimetics thereof. Derivatives include chemically modified derivatives explained below including CMK modified peptides.
- Other suitable peptides include Phe-Leu-Phe (FLF); Glu-Pro-Phe (EPF); Ala-Phe-Leu-Phe (ALPF); Lys-Ala-Leu (KAL); Arg-Ala-Val (RAV), Asp-Thr-Glu-Phe (DTEF), Ala-Pro-Leu (APL), Pro-Gln-Arg (PQR), Arg-Pro-Leu (RPL); and derivatives or peptidomimetics thereof. Derivatives include chemically modified derivatives explained below including chloromethyl ketones (CMK) modified peptides.
- According to one embodiment, the agent may directly inhibit IL-36 proteolytic processing by binding to the protease cleavage sites within IL-36 required for activation of IL-36 and/or competing with the IL-36 activating proteases, such as cathepsin G, elastase or cathepsin K, cathepsin C(DPPI) or proteinase-3, for binding to their respective cleavage sites within IL-36 required for activation of IL-36. In this manner the agent of the invention is designed to target and/or mimic the protease cleavage sites within IL-36 required for activation of IL-36 (IL-36α, IL-36β and/or IL-36γ).
- Additionally, in addition to targeting the protease cleavage sites within IL-36 required for activation of IL-36, the agent may also target and/or mimic one or more amino acid residues downstream and/or upstream of the protease cleavage site.
- For example, the agent may target IL-36β cleavage site, R (amino acid residue 5), and optionally one or more of the surrounding downstream residues N, P and/or Q (NPQR5).
- Additionally, the agent may target the IL-36γ cleavage site V (amino acid residue 15) and optionally one or more of the surrounding downstream residues G, R and or V (GRA
V 15). - Additionally, the agent may target the IL-36α cleavage site K (amino acid residue 3) and/or cleavage site A (amino acid 4) and optionally one or more of the surrounding downstream residues MEK3 A4(SEQ ID No. 28). We have found tha Cathepsin G cleaves IL-36α at residue K(3) while elastase cleaves at residue A(4).
- Ideally, the agent targets both the cleavage site and one or more of the surrounding upstream and downstream residues, including for example, IL-36β cleavage site NPQ
R 5 EAPP (SEQ ID No. 1) or the IL-36γ cleavage sites GRAV 15 YQSM (SEQ ID No. 2) or IL-36α cleavage sites MEK3 A4 LKID (SEQ ID No. 28). In this manner one or more additional amino acid residue selected from N, P and/or Q and one or more additional amino acid residues selected from E, A, P and/or P may be targeted for IL-36 β. Additionally, one or more additional amino acid residue selected from G, R and/or V and one or more additional amino acid residues selected from Y, Q, S and/or M may be targeted for IL-36 γ. Additionally, one or more additional amino acid residue selected from M, E, K, and/or A and one or more additional amino acid residues selected from L, K, I, and/or D may be targeted for IL-36α - Full details of IL-36 including GenBank IDs and the cleavage sites are listed below. The cleavage sites within each amino acid sequence are underlined below.
-
-
- GenBank: BC101833.1 (DNA sequence) as shown in
FIG. 36 (SEQ ID No. 3) - >gb|BC101833.1|:63-536 Homo sapiens
interleukin 1 family, member 8 (eta), mRNA (cDNA clone MGC:126882 IMAGE:8069339), complete cds - GenBank: AAI01834.1 (Amino acid sequence) SEQ ID No. 4
- >gi|75517955|gb|AA101834.1|
Interleukin 1 family, member 8 (eta) [Homo sapiens]
- GenBank: BC101833.1 (DNA sequence) as shown in
-
- NPQR is a protease cleavage site within IL-36β which is required for the activation of IL-36β. DTEF (also underlined) is another protease cleavage site that is cleaved by cathepsin G, however, we understand that DTEF is not required for activation of IL-36B.
IL-36γ (IL-36G) DNA and amino acid sequence: - GenBank: BC098337.1 (DNA sequence) as shown in
FIG. 37 (SEQ ID No. 5) - >gb|BC098337.1|:25-534 Homo sapiens
interleukin 1 family,member 9, mRNA (cDNA clone MGC:119102 IMAGE:40003612), complete cds - The coding region (CDS) for IL-36γ comprises
nucleotides 25 to 534 from the entire IL-36γ sequence which comprisesnucleotide 1 to 791. - GenBank: AAH98337.1 (Amino acid sequence) (SEQ ID No. 6)
- >gi|68226701|gb|AAH98337.1 I Interleukin 1 family, member 9 [Homo sapiens]
- NPQR is a protease cleavage site within IL-36β which is required for the activation of IL-36β. DTEF (also underlined) is another protease cleavage site that is cleaved by cathepsin G, however, we understand that DTEF is not required for activation of IL-36B.
-
- GRAV is a protease cleavage site within IL-36γ which is required for the activation of IL-36γ.
IL-36α (IL-36A) DNA and amino acid sequence: - GenBank: NM 014440.1 (DNA sequence) as shown in
FIG. 38 (SEQ ID No. 26) - >gi|7657091|ref|NM_014440.1| Homo sapiens
interleukin 36, alpha (IL36A), mRNA - GenBank: NP_055255.1 (Amino acid sequence) SEQ ID No. 27
- >gi|7657092|ref|NP_055255.11 interleukin-36 alpha [Homo sapiens] SV=1
- GRAV is a protease cleavage site within IL-36γ which is required for the activation of IL-36γ.
- MEK3 is a protease cleavage site of cathepsin-G within IL-36a, which is required for the activation of IL-36a. MEKA4 is a protease cleavage site of elastase within IL-36a, which is required for the activation of IL-36a.
- These findings have led to the generation of agents, preferably synthetic peptides, peptides derivatives and peptidomimetics thereof, which aim to target and/or mimic the IL-36 protease cleavage sites which directly inhibit IL-36 activation via proteolytic processing.
- According to one embodiment, the peptides are tri-peptide and tetra-peptides or peptides derivatives and peptidomimetics thereof which aim to target and/or mimic the IL-36 protease cleavage sites which directly inhibit IL-36 activation via proteolytic processing.
- These peptides are designed to target and/or mimic the new protease cleavage sites identified. The peptides can be conventionally designed to target and/or mimic these new protease cleavage site using standard chemistry techniques (e.g. Thornberry et al., A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74; Nicholson et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43; Powers J C et al, Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-750. (2002); Merrifield, R. B. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide, J. Am. Chem. Soc., 85, 2149-2154 (1963); Nilsson, B. L., Soellner, M. B., Raines, R. T. Chemical Synthesis of Proteins. Annu. Rev. Biophys. Biomol. Struct 2005; 34: 91-118 (2005)).
- The agents may be a peptide which mimics the protease cleavage sites within IL-36β, IL-36γ and/or IL-36α required for activation of IL-366, IL-36γ and/or IL-36α and binds said protease cleavage sites to inhibit its activity; or derivatives or peptidomimetics thereof.
- Suitable peptide derivatives include chemically modified peptides. Chemical modifications to the peptides aim to increase stability and efficiency. Furthermore, the coupling or combinations of peptides using chemical linkers may also be contemplated. Chemical modifications include addition of chloromethyl ketones (CMK), fluoromethyl ketone (FMK), and aldehyde/formyl group (R-CHO) to the C-terminus (carboxyl group) to increase potency, through the formation of irreversible or reversible bonds with the target proteases active site amino acid (e.g. serine, cysteine), such that lower concentrations of peptides are required to achieve inhibition.
- Additional chemical modifications may include addition of protection groups to the N-terminus (amino group) to stabilizes the tri-/tetra-peptide and protect it from degradation; including N-benzyloxycarbonyl (Benzyl carbamate), butyl carbamate, Acetamide, phthalimide, benzylamine, triphenylmethylamine, benzylideneamine, p-toluenesulfonamide.
- Preferred chemical modifications or derivates include:
-
- Cyclization: Cyclization is typically carried out using side chains or N-/C-terminal regions of the peptide sequence through the formation of disulfide bonds. For example, lanthionine, dicarba, hydrazine or lactam bridges. Advantages to cycling peptides are to reduce hydrophilicity, decrease conformational flexibility, enhance membrane permeability and increase stability to proteolysis.
- PEGylation: is the process of both covalent and non-covalent attachment of polyethylene glycol (PEG) polymer chains to molecules and macrostructures, such as a peptide, a therapeutic protein or antibody. Advantages to PEGylation include slowed systemic clearance and increased absorption.
- Lipidization: is the addition of fatty acids to a peptide or protein to increase the lipophilicity of the peptides by forming a stable amide bond between a carboxyl group of a lipid molecule and an amino group of a peptide or protein. Advantages include improved transport across biological membrane, higher stability and longer plasma half-life.
- N-acetylation: The addition of a acetyl functional group to the N-terminus of a peptide. Advantages include increased metabolic stability, resistance to proteolytic degradation and increased bioavailability of the peptide.
- D-AA: is the substitution of natural L-amino acids with D-amino acids. Advantages to D-amino acid substitution can result in increased resistance to proteolytic degradation and improved stability.
- Cross-linking: These are a-helical peptides containing a synthetic hydrocarbon backbone linking various residues. The backbone, referred to as the staple, locks the conformation of the peptide increasing it helicity, stability and increased cell penetration. [REF:34]
- Peptidomimetics are also contemplated, involving modifiying the peptides themselves or by designing an alternative compound/composition which mimics the peptide. Conventional techniques may be used to generate such peptidomimetics.
- Table 1 provides a list of exemplary tri-peptides and tetra-peptides designed to mimic the protease cleavage sites of the invention. CMK altered derivatives of these tri-peptide and tetra-peptides may also be used.
-
TABLE 1 Exemplary Agents and derivatives thereof which mimic and/or target the IL-36 protease cleavage sites AGENT TARGETS II-36 AGENT WITH CMK derivative thereof ISOFORM Lys-Ala-Leu (KAL); IL-36α KAL-CMK Ala-Leu-Ala (ALA); IL-36α ALA-CMK Met-Ala-Leu-Ala (MALA) (SEQ ID No. 29); IL-36α MALA-CMK; Asp-Pro-Gln-Arg (NPQR) (SEQ ID No. 30); IL-36β NPQR-CMK; Pro-Gln-Arg (PQR); IL-36β PQR-CMK; Gln-Arg-Glu-Ala (QREA) (SEQ ID No. 31); IL-36β QREA-CMK Arg-Ala-Val (RAV) IL-36γ RAV-CMK Gly-Arg-Ala-Val (GRAV) (SEQ ID No. 32); IL-36γ GRAV-CMK Ala-Val-Tyr-Gln (AVYQ) (SEQ ID No. 33); IL-36γ AVYQ-CMK; - The skilled man would understand that these peptides have been designed to bind and/or mimic the respective IL-36 protease active site and effectively compete with the substrate, IL-36, for proteolysis. This is governed by electrostatic interactions between the protease active site and the peptide which mimics the proteolytic cleavage site of a naturally occurring substrate. Therefore, an effective amount of these peptide this will result in reversible inhibition, as the active site of the protease will be occupied by the tri/tetra-peptide, thus protecting the substrate, IL-36, from proteolysis.
- In the case of CMK modified peptides, the CMK chemical group located at the C-terminus of the peptide will similarly occupy the active site but will form a covalent bond resulting in irreversible inhibition of the protease. (REF:35)
- According to another embodiment, the agent may indirectly inhibit IL-36 proteolytic processing by preventing and/or inhibiting the activity of proteases which proteolytically process IL-36.
- According to a one embodiment, the agent of the invention may be a conventional cysteine protease inhibitor or a serine protease inhibitor. Other proteases may be used as described above.
- This is based on our finding that cysteine proteases including cathepsin-C/DPPI and cathepsin K and the serine proteases including cathepsin G, elastase and proteinase-3 have a role in activating IL-36 via proteolytic processing.
- Serine proteases are characterised by a distinctive structure, consisting of two beta-barrel domains that converge at the catalytic active site. The catalytic triad of a serine protease consists of a Serine-Histidine-Aspartic acid (Ser-His-Asp), whereby the serine is the nucleophillic residue. Suitable serine protease inhibitors which may be used in the invention bind into the active site of the protease, typically exploiting the nucleophilic serine, either forming stable acyl intermediates (sulphonyl flourides/chlorides, phosphonates), or stable tetrahedral intermediates (aldehydes, halomethyl ketones, boronic acids.)
- Accordingly, it will be understood that additional serine protease inhibitors may also be utilised in the present invention. Suitable serine protease inhibitors may be selected from the following groups:
-
- Trypsin-like serine proteases: Trypsin-like proteases cleave peptide bonds following a positively charged amino acid (lysine (K) or arginine (R). This specificity is driven by the residue, which is located at the base of the enzyme's S1 pocket, typically a negatively charged aspartic acid (D) or glutamic acid (E).
- Chymotrypsin-like serine proteases: The S1 pocket of chymotrypsin-like enzymes is more hydrophobic than in trypsin-like proteases. A consequence of this is that there is a specificity for medium to large sized hydrophobic residues, such as tyrosine (Y), phenylalanine (F) and tryptophan (W).
- Elastase-like serine proteases: Elastase-like proteases have a smaller S1 cleft than either trypsin- or chymotrypsin-like proteases. Consequently, residues such as alanine (A), glycine (G) and valine (V) tend to be preferred.
- Subtilisin-like serine proteases: Subtilisin is a serine protease in prokaryotes. Subtilisin share the same catalytic mechanism as chymotrypsin-like utilising a catalytic triad, to create a nucleophilic serine.
- According to a preferred embodiment, one or more serine proteases selected from serine protease families S1 to S81 (MEROPS classification system) may be used.
- According to a preferred embodiment, the agent of the invention may be a naturally occurring serine protease inhibitors from the serpin family and the chelonianin family.
- Members of the serpin family include α1-Antichymotrypsin, α1-Antitrypsin, SerpinB1, PI6, PI9. It is known that serpins inhibit proteases by a suicide substrate inhibition mechanism. The protease initially recognizes the serpin as a potential substrate using residues of the reactive center loop (RCL) and cleaves it between P1 and P1′. This cleavage allows insertion of the cleaved RCL into the β-sheet A of the serpin, dragging the protease with it and moving it over 71 Å to the distal end of the serpin resulting in a 1:1 stoichiometric covalent inhibitory complex. The protease is distorted into a conformation, where the acyl enzyme intermediate is hydrolysed extremely slowly.
- Members of the chelonianin family include SLPI and Elafin.
- Cysteine protease are characterised by a common catalytic mechanism. The catalytic triad of a cysteine protease consists of a cysteine-histidine-aspartic acid (Cys-His-Asp), whereby the cysteine is the nucleophillic residue. We postulate that other cysteine proteases may work in accordance with the invention. These include naturally occurring cysteine protease inhibitors from cysteine families C1-C110 (MEROPS classification).
- Based on our surprising findings that the neutrophil-derived proteases elastase, cathepsin G, cathepsin K orcathepsin-C/DPPI process and activate IL-36. Thus, according to a preferred embodiment of the invention the agent may be designed to prevent the binding of elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI, or other related proteases to IL-36 and to prevent conversion of IL-36 to its active form by elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI,_ or other neutrophil-derived proteases.
- We have also found that cathepsin K, a protease predominantly expressed in osteoclasts, can cleave and activate IL-36 β (beta) at the same residue as Cathepsin G (NPQR5 EAAP).
- Furthermore, DPPI is an enzyme expressed in neutrophil granules that processes the neutrophil proteases (Elastase, Cathepsin G and proteinase 3) into fully active proteases. DPPI is responsible for the activation of a number of proteases, which include CatG, elastase, proteinase-3 granzyme A, granzyme B, granzyme C and chymase. In this manner, DPPI is an activator of IL-36 proteases. Targeted inhibition of DPPI would be an indirect way in which to suppress IL-36 activation.Dipeptide-derived diazoketones, such as Gly-Phe-CHN2 (Gly-Phe-diazomethane) can be used to inhibit DPPI.
- In this manner, the agent may be a conventional elastase, cathepsin G, proteinase-3, cathepsin K or cathepsin-C/DPPI inhibitor as highlighted in Table 2 below.
- It will be understood that the agent of the invention may be a small molecule or a biologic including, peptides, polypeptide, protein, siRNA, antibody, and/or targeted genome editing/sgRNA e.g CRISPR-Cas system. sgRNA relates to the emerging CRISP/Cas9 genome editing technology.
-
TABLE 2 Exemplary Agents which indirectly inhibit activation of IL-36 proteolytic processing by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof Agent Type Protease Target SERINE PROTEASE INHIBITORS (SMALL MOLECULE) Boswellic Acids Cathepsin G inhibitor (serine protease) cathepsin G inhibitor I Cathepsin G inhibitor (serine protease) Elastase inhibitor IV Elastase inhibitor (serine protease) Sodium Fluoride Ser/Thr and acidic phosphatases 4-(2-Aminoethyl) benzenesulfonyl fluoride Non-specific serine protease hydrochloride (AEBSF•HCl) inhibitor phenylmethanesulfonylfluoride (PMSF) Non-specific serine protease inhibitor dipeptide-derived diazoketones, such as DPPI/Cathepsin C inhibitor Gly-Phe-CHN2 (Gly-Phe-diazomethane) (cysteine protease) Vinyl sulfones such as Ala-Hph-VS-Ph DPPI/Cathepsin C inhibitor (cysteine protease) Odanacatib ™ (MK-0822) (N-(1- Cathepsin K inhibitor (cysteine cyanocyclopropyl)-4-fluoro-N2-{(1S)- protease) 2,2,2-trifluoro-1-[4′-(methylsulfonyl) biphenyl-4-yl]ethyl}-L-leucinamide) Balicatib ™ (N-[1- Cathepsin K(cysteine protease) (cyanomethylcarbamoyl)cyclohexyl]-4-(4- propylpiperazin-1-yl)benzamide) MV061194 Cathepsin K(cysteine protease) SERINE PROTEASE INHIBITORS (BIOLOGIC) Aprotinin ™ (small protein bovine Non-specific serine protease pancreatic trypsin inhibitor (BPTI)) inhibitor Leupeptin ™ (N-Acetyl-leucyl-N-{(5- Non-specific serine protease [(diaminomethylidene)amino]-1- inhibitor oxopentan-2-yl}-leucinamide) - According to a preferred embodiment of the invention, the agent may be a small molecule or biologic inhibitor of cathepsin G and elastase is selected from known serine protease inhibitors and cathespin K inhibitors including but not limited to cathepsin G inhibitor I, Elastase inhibitor IV, Sodium Fluoride, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF⋅HCl), Aprotinin, Leupeptin, phenylmethanesulfonylfluoride (PMSF), Boswellic Acids,
cathepsin K inhibitor 1, and/or Odanacatib (cathepsin K inhibitor). - According to another embodiment, the agent of the invention may be a peptide from 3 to 10 amino acids in length, comprising or consisting of 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, that binds an IL-36 activating protease and/or competes with IL-36 activating proteases for access to the IL-36 cleavage sites.
- Ideally, the peptide is a tripeptide or tetrapeptide, although longer peptide chains may be used. Optionally the peptide may be up to 8-10 amino acids in length.
- According to one embodiment of the invention, the peptide, which may be a tripeptide or tetrapeptide, binds to the IL-36 neutrophil-derived protease and/or competes with neutrophil-derived proteases for access to the IL-36 neutrophil-derived protease cleavage sites.
- Additionally, the peptide of the invention may be linked to form multi-peptide combinations, comprising for example from 2 to 20 tripeptide or tetrapeptide units. Optionally, the multi-peptide combination comprises 6/8, 9/12 or 12/16 multiples of tripeptides or tetra peptides. As described below the peptides may be chemically linked to form multi-peptide combinations.
- In this manner, the peptides target the proteases directly. The peptide sequences (e.g. tri/tetra peptides etc as outlined below) are designed to mimic and/or target the cleavage sites and motifs within the IL-36 proteins to act as targets for any proteases, thereby, protecting IL-36 from proteolysis.
- These peptides may be designed and manufactured using standard chemistry techniques (e.g. Thornberry et al., A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74; Nicholson et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43; Powers J C et al, Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-750. (2002); Merrifield, R. B. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide, J. Am. Chem. Soc., 85, 2149-2154 (1963); Nilsson, B. L., Soellner, M. B., Raines, R. T. Chemical Synthesis of Proteins. Annu. Rev. Biophys. Biomol. Struct 2005; 34: 91-118 (2005))
-
TABLE 3 Exemplary synthetic peptides which indirectly inhibit activation of IL-36 proteolytic processing by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof SYNTHETIC PEPTIDE AGENT AGENT INHIBITS THE ACTIVITY OF TARGETS THE FOLLOWING IL-36 ACTIVATING II-36 AGENT PROTEASES ISOFORM Phe-Leu-Phe (FLF) Cathepsin G-inhibitory peptides IL-36β Glu-Pro-Phe (EPF) Cathepsin G-inhibitory peptides IL-36β Ala-Phe-Leu-Phe (AFLF) Cathepsin G-inhibitory peptides IL-36β (SEQ ID No. 7) Lys-Ala-Leu (KAL) Phe-Leu-Phe (FLF-CMK) Cathepsin G-inhibitory peptides IL-36β Glu-Pro-Phe-CMK (EPF- Cathepsin G-inhibitory peptides IL-36β CMK) Ala-Phe-Leu-Phe-CMK Cathepsin G-inhibitory peptides IL-36β (AFLF-CMK) Lys-Ala-Leu-CMK (KAL- Cathepsin G/Elastase-inhibitory IL-36α CMK) peptides Arg-Ala-Val (RAV) Elastase-inhibitory peptides IL-36γ Asp-Thr-Glu-Phe (DTEF) Elastase/Proteinase-3-inhibitory IL-36γ (SEQ ID No. 8) peptides Ala-Pro-Leu (APL) Elastase/ Proteinase-3-inhibitory IL-36γ peptides Pro-Gln-Arg (PQR) Elastase/ Proteinase-3-inhibitory IL-36γ peptides Arg-Pro-Leu (RPL) Elastase/ Proteinase-3-inhibitory IL-36γ peptides - The rationale for designing peptides Arg-Ala-Val (RAV), Asp-Thr-Glu-Phe (DTEF), Ala-Pro-Leu (APL), Pro-Gln-Arg (PQR), Arg-Pro-Leu (RPL) was to inhibit elastase activity, centered around tri-peptide motifs that elastase preferentially cleaves (see
FIG. 32 ). CMK modified Arg-Ala-Val (RAV), Asp-Thr-Glu-Phe (DTEF), Ala-Pro-Leu (APL), Pro-Gln-Arg (PQR), Arg-Pro-Leu (RPL) are also contemplated. - As described above, chemical modifications to the peptides aim to increase stability and efficiency. Furthermore, the coupling or combinations of peptides using chemical linkers may also be contemplated. Chemical modifications include addition of chloromethyl ketones (CMK), fluoromethyl ketone (FMK), and aldehyde/formyl group (R-CHO) to the C-terminus (carboxyl group) to increase potency, through the formation of irreversible or reversible bonds with the target proteases active site amino acid (e.g. serine, cysteine), such that lower concentrations of peptides are required to achieve inhibition.
- Additional chemical modifications may include addition of protection groups to the N-terminus (amino group) to stabilizes the tri-/tetra-peptide and protect it from degradation; including N-benzyloxycarbonyl (Benzyl carbamate), butyl carbamate, Acetamide, phthalimide, benzylamine, triphenylmethylamine, benzylideneamine, p-toluenesulfonamide.
- Combinations of peptides may be used that simultaneously target both elastase, cathepsin G or cathepsin K. In one embodiment of the invention, candidate peptides that target both elastase and cathepsin G and/or cathepsin K may be “linked” via a chemical linker. According to another aspect of this, the agent may chemically cross-link two or more peptides to form multi-peptide combinations
- According to a preferred embodiment the peptide may be selected from the peptides listed within the following table
-
TABLE 4 Tri/Tetra Peptides Glu-Pro-Phe (EPF) (SEQ ID No. 7) Ala-Phe-Leu-Phe (AFLF) Lys-Ala-Leu (KAL) Glu-Pro-Phe-CMK (EPF-CMK) Ala-Phe-Leu-Phe-CMK (ALFL-CMK) Lys-Ala-Leu-CMK (KAL_CMK) Arg-Ala-Val (RAV) (SEQ ID No. 8) Asp-Thr-Glu-Phe (DTEF) Ala-Pro-Leu (APL) Pro-Gln-Arg (PQR) Arg-Pro-Leu (RPL)
or chemically modified derivatives thereof or combinations thereof. - According to yet another aspect of the invention, the antibody may be a polyclonal or monoclonal antibody raised against IL-36 activating proteases, including the proteases elastase or cathepsin G, K or C. In this manner, the antibody binds to the IL-36 activating protease to prevent the protease binding to the protease cleavage sites within IL-36.
- According to another aspect of the invention, the antibody may be a polyclonal or monoclonal antibody raised against the protease cleavage site amino acid sequence within IL-36, preferably IL-36β and IL-36γ. In this manner, the antibody binds the amino acid sequence encompassing the protease cleavage site within IL-36 to block access of the IL-36 activating protease to the IL-36 cleavage sites.
- It will be understood that the present invention may be directed to the treatment of inflammation of barrier organs in a subject, including inflammation of the skin, gut and/or lung.
- Ideally, the present invention may be used in the treatment of inflammatory skin disorders, such as psoriasis, including Psoriasis vulgaris, dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris. For example, plaque, guttate, palmoplantar, generalized pustular and/or arthritic psoriasis may be treated in accordance with the invention. Psoriasis will be understood to cover all forms of psoriasis inclusing psoriasis vulgaris, plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, arthritic psoriasis, palmoplanter pustulosis and psoriatic nail disease.
- According to a second aspect of the invention, there is provided a composition comprising an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- The agents described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. In one embodiment, the present invention relates to a pharmaceutical composition comprising an agent of the invention described herein, and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. In one embodiment, the present invention is a pharmaceutical composition comprising an effective amount of an agent of the present invention and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
- Suitable pharmaceutical excipients include but are not limited to binders, disintegrants, fillers, flavours, colours, lubricants, glidants, sorbents and/or preservatives.
- It will be understood that the agent capable of inhibiting IL-36 activation via proteolytic processing may be adapted for administration in the following alternative forms tablets, capsules, oral liquids, transdermal patches, injectable products, implants, eye products, nasal products, inhalers and suppositories.
- The compositions of the invention can also be in liquid form, for example, solutions, emulsions, suspensions or syrups.
- The invention is also directed to agents which target and/or mimic one or more of the following IL-36 protease cleavage sites
-
- the IL-36β protease cleavage site NPQR5 and/or one or more of upstream amino acid residues EAAP;
- the IL-36γ cleavage site GRAV15 and/or one or more of upstream amino acid residues YQSM; and/or
- the IL-36α protease cleavage sites MEK3 or and MEKA4 and/or one or more of upstream residues LKID.
- The invention is also directed to agents which inhibit IL-36 activation via proteolytic processing by preventing and/or inhibiting the activity of IL-36 activating proteases or activators thereof selected from elastase, cathepsin G, cathepsin K, proteinase-3 and DPPI (Cathepsin C).
- Preferably, the agent comprises or consists of the peptides listed in Tables 1 and 3, or derivatives, peptidomimetic or combinations thereof.
- According to a third aspect of the invention, there is provided a comprising an agent capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient. It will be understood that the agent, is as defined above, and inhibits IL-36 activation by binding to the IL-36 protease cleavage sites required for activation of IL-36; or the agent prevents and/or inhibits the activity of IL-36 activating proteases or activators thereof.
- Ideally, the composition is for topical treatment although other administration routes, for example oral, parenteral, intravenous are also contemplated.
- According to one embodiment, there is provided a topical inflammatory composition, ideally a skin disorder treatment composition, comprising an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- Preferably, the composition is adapted for the treatment and prevention of inflammatory skin disorders and comprises an agent capable of inhibiting IL-36 activation via proteolytic processing and a suitable pharmaceutical excipient.
- The topical treatment composition may be in the form of a cream or gel. Accordingly, the suitable pharmaceutical excipient may be any conventional topical pharmaceutical excipient.
- Ideally, the agent is a small molecule, peptide, polypeptide, protein, siRNA, sgRNA, and/or antibody. For example, the agent may be selected from Table 1, 2 or 3.
- According to a fourth aspect of the invention, there is provided an agent as described above which is capable of inhibiting IL-36 activation via proteolytic processing for use in the manufacture of a medicament for the treatment and/or reduction of inflammation, preferably inflammatory skin disorders, in a subject.
- According to a fifth aspect of the invention, there is provided a method for the treatment and/or reduction of inflammation in a subject, preferably inflammation of barrier organs, including inflammation of the skin, gut and/or lung, comprising administering an effective amount of an agent as described above which is capable of inhibiting IL-36 proteolytic processing to a subject.
- The subject is a subject suffering from an inflammatory skin disorder selected from psoriasis, including Psoriasis vulgaris; dermatitis and/or acne, sebaceous cysts, vasculitis, eczema, dermatitis, granuloma annulare, lichen planus, bullous pemphigoid, molluscum contagiosum, dermatomyositis and ichthyosis vulgaris. Ideally, plaque, guttate, palmoplantar, generalized pustular and/or arthritic psoriasis may be treated in accordance with the invention. Psoriasis will be understood to cover all forms of psoriasis inclusing psoriasis vulgaris, plaque psoriasis, guttate psoriasis, flexural (inverse) psoriasis, erythroderma psoriasis, generalized pustular psoriasis, arthritic psoriasis, palmoplanter pustulosis and psoriatic nail disease.
- The subject is ideally a mammal, preferably a human.
- Preferably, the agent capable of inhibiting IL-36 proteolytic processing may be applied topically to the subject.
- The present invention will now be described by the following non-limiting figures and examples.
- The Invention will be more clearly understood from the following description of embodiments thereof, given by way of example only, with references to the accompanying drawings, in which—
-
FIG. 1 (A) is a schematic of modified forms of IL-36α, IL-36β and IL-36γ where a caspase-3-processing motif (DEVD) was inserted into the IL-36 sequence, N-terminal to the known processing sites. (B) IL-36α/β/γ and DEVD-IL-36α/β/γ were incubated at 37° C. for 2 h, either alone or in the presence of indicated concentrations of recombinant caspase-3, followed by analysis by immunoblot. -
FIG. 2 (A) are graphs showing HeLaVector and HeLaIL36R stimulated with caspase-3 cleaved DEVD-IL36α, β and γ. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. (B) are graphs showing HeLaIL36R stimulated with full-length or caspase-3 cleaved DEVD-IL-36α, β and γ. At indicated time-points cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 3 are graphs showing HeLaIL36R were stimulated with (A) full-length DEVD-IL-36α or caspase-3 cleaved DEVD-IL-36α, (B) full-length DEVD-IL-36β or caspase-3 cleaved DEVD-IL-36β, (C) full-length DEVD-IL-36γ or caspase-3 cleaved DEVD-IL-36γ at the indicated concentrations. (D) showing HaCat stimulated with full-length DEVD-IL-36β or caspase-3 cleaved DEVD-IL-36β at the indicated concentrations. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 4 (A) are photographs showing primary blood derived neutrophils stimulated in the presence or absence of PMA (50 nM) for 3 h. (B) are graphs showing HeLaIL36R were stimulated with 500 pM IL36α, β and γ pre-incubated for 2 h at 37° with indicated dilutions of either control or PMA-activated degranulates. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 5 are graphs showing HeLaIL36R stimulated with IL36α, IL36β and IL36γ, pre-incubated for 2 h at 37° with neutrophils degranulates in the presence or absence of PMSF (1 mM), leupeptin (10 μg/ml), aprotinin (10 mg/ml), Cathepsin G inhibitor 1 (10 μM), zVAD-fmk (10 μM), Elastase Inhibitor IV (10 μM), ALLN (5 μM), Antipain (100 μM). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 6 (A and B) are graphs showing Control and PMA-activated neutrophil degranulates that were pre-incubated with biotin-VAD-CMK (10 μM), biotin-FLF-CMK (10 μM) or Elastase Inhibitor IV (10 μM) for 30 min on ice followed by incubation with strepavidin agarose beads. Degranulates were subsequently assessed for Cathepsin G activity by FLF-sBzl hydrolysis assay (A) or Elastase activity was assessed by AAPV-AMC hydrolysis. HeLaIL36R were stimulated with IL36β (A) or IL36γ (B) pre-incubated for 2 h at 37° with mock, biotin-VAD-CMK (10 μM) or biotin-FLF-CMK (10 μM) treated degranulates. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 7 (A) are graphs showing hydrolysis of the synthetic caspase peptide (WEHD-AMC), by caspase-1; the caspase peptide (DEVD-AMC), by caspase-3; the cathepsin peptide (Suc-FLF-sBzL), by purified neutrophil cathepsin G; the elastase peptide (AAPV-AMC), purified neutrophil elastase. (B) are graphs showing HeLaIL36R stimulated with 500 pM IL-36α, β and γ pre-incubated for 2 h at 37° with indicated concentrations of recombinant caspase-1,-3 or purified cathepsin-G and elastase. IL-1β p17 served as a positive control for caspase titrations. After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 8 are graphs showing HeLaIL36R stimulated with a titration of IL-36α, β and γ pre-incubated for 2 hr at 37° with fixed concentrations of purified cathepsin-G (50 nM) and elastase (200 nM). After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 9 (A) is a Coomassie blue stained gel of recombinant IL-36β that was incubated in the presence or absence of Cathepsin G (50 nM). Indicated fragments were analysed by Edman Degradation sequencing and novel N-termini were identified as (6EAAP) and (54SDKE). (B) is schematics representing NPQR5 and DTEF53 cleavage motifs within IL-36β and point mutants IL-36β F53A and IL-36β R5A. -
FIG. 10 is a Coomassie blue stained gel of recombinant Recombinant IL-36β, IL-36βF63A and IL-36βR5A were incubated with fixed concentration of cathepsin-G, as indicated, followed by analysis by SDS-PAGE and Coomassie stain. Representative gel is shown from at least two independent experiments. -
FIG. 11 (A) are graphs showing HeLaIL36R SEAP stimulated with a titration of IL36β and IL36βR5A pre-incubated for 2 h at 37° with cathepsin-G (50 nM). After 24 h, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA. (B) HeLaIL36R stimulated with 500 pM of IL36β, IL-36βR5A and IL36βF53A pre-incubated for 2 h at 37° with a titration of cathepsin-G. After 24 h, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 12 are graphs showing HeLaIL36R stimulated with 500 pM of IL36β, IL-36βR5A and IL36βF53A pre-incubated for 2 h at 37° with a titration of PMA-activated neutrophil degranulate. After 24 hr, NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 13 (A) is a Coomassie blue stained gel of recombinant IL-36γ that was incubated in the presence or absence of Elastase (100 nM). Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as (16YQSM). (B) is schematics representing GRAV16 cleavage motif within IL-36γ and the point mutant IL-36γ V15A. -
FIG. 14 (A) is a graph showing recombinant IL-36γ and IL-36γV15A incubated with a titration of Elastase or (B) fixed dose of Elastase (80 nM). After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 15 are graphs showing recombinant IL-36γ and IL-36γV15A incubated with a titration of PMA-activated neutrophil degranulate. After 24 hr, (A) NF-KB activity was measured as a fold iduction of SEAP in the supernatant and (B) cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 16 are graphs showing HaCat stimulated with indicated titration of IL36α, β and γ pre-incubated for 2 h at 37° with cathepsin-G (50 nM), elastase (100 nM). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 17 are graphs showing primary keratinocytes stimulated with indicated titration of IL36α, β and γ pre-incubated for 2 h at 37° with cathepsin-G (50 nM), elastase (100 nM). After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 18 are photographs of graphs showing Organotypic skin reconstructs cultivated at the air to liquid interface were topically stimulated with either cathepsin-G alone (We applied 2 μl in 10 μl MM), 2 nM IL-36βFL or IL-36βCatG in a volume of 10 μl MM, respectively, every other day. Application of 10 μl MM only served as negative control. After 15 days skin reconstructs were harvested, fixed in paraffin, and sections stained with H&E, against filaggrin, involucrin,cytokeratin -
FIG. 19 is a gene expression heat map of IL-36βCatG induced in primary keratinocytes at 8 h. -
FIG. 20 are graphs showing primary keratinocytes stimulated with IL-36βFL (5 nM) and IL-36βCatG (5 nM). At indicated time-points mRNA levels of cytokine were determined by RT-PCR. -
FIG. 21 (A-B) are graphs showing primary keratinocytes stimulated with IL-36βFL (5 nM) and IL-36βCatG (5 nM). At indicated time-points levels of cytokine were determined by ELISA. (C) graphs showing primary keratinocytes stimulated with indicated concentrations of recombinant IL-17C. After 48 h, levels of cytokine were determined by ELISA. -
FIG. 22 are immunoblots showing the specificity and cross-reactivity of IL-36 rabbit polyclonal antibodies tested against indicated protein amounts of recombinant IL-36 ligands. -
FIG. 23 (A) are immunoblots showing Primary keratinocytes treated with a titration of IL-36βCatG (10, 5, 2.5 nM), PMA (40, 20, 10 nM) and Poly:IC (100, 50, 25 mg/ml). Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot. (B) Primary keratinocytes treated with fixed concentrations of IL-36βCatG (5 nM), PMA (20 nM) and Poly:IC (100 μg/ml) over indicated time-points. Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot. -
FIG. 24 (A) are immunoblots showing HaCat treated with a titration of IL-36βCatG (10, 5, 2.5 nM), PMA (40, 20, 10 nM) and Poly:IC (100, 50, 25 mg/ml). Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot. (B) HaCat treated with fixed concentrations of IL-36βCatG (5 nM), PMA (20 nM) and Poly:IC (100 μg/ml) over indicated time-points. Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot. -
FIG. 25 (A) are photographs showing primary keratinocytes incubated in the presence or absence of PMA (20 nM) for 12 h, followed by 1 h incubation with SLO (5 μg/ml). (B) is a graph showing primary keratinocytes incubated with indicated concentrations of SLO, followed by transfers of the supernatants onto HelaIL36R cells. After 24 h, cytokine concentrations in culture supernatants were determined by ELISA. Cell death is measured by annexin V/PI staining and quantified by flow cytometry. Cells and supernatants were analysed for indicated proteins by immunoblot. -
FIG. 26 (A) is an immunoblot showing endogenous and recombinant IL-36γ incubated for 1 h at 37° with buffer, elastase (100 nM), cathepsin-G (50 nM), and neutrophil degranulate (1/4 dilution). (B) is an immunoblot showing endogenous IL-36γ incubated for 1 h at 37° with indicated concentrations of elastase, cathepsin-G and neutrophil degranulate. -
FIG. 27 (A) is an immunoblot of control versus psoriatic biopsy samples, analysed for indicated proteins. Recombinant IL-36 (500 pg) serves as a positive control for each immunoblot. (B) is an immunoblot showing endogenous IL-36γ from psoriatic skin incubated for 1 h at 37° in the presence or absence of elastase (100 nM). -
FIG. 28 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 μM) followed by addition of IL36α for 2 h at 37°. HeLaIL36R were stimulated for 24 h. IL-8 cytokine concentrations in culture supernatants were determined by ELISA. Note: AFLF, GLF peptides and Elast I-IV serve as negative controls for IL-36α assay. -
FIG. 29 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 pM) followed by addition of IL36β for 2 h at 37°. HeLaIL36R were stimulated for 24 h. IL-6 cytokine concentrations in culture supernatants were determined by ELISA. Note: Elast I-IV serves as negative controls for IL-36β assay. -
FIG. 30 are graphs showing cathepsin-G were pre-incubated for 30 min on ice in the presence or absence of peptide (10 μM) followed by incubation with IL36β. HeLaIL36R SEAP were stimulated with samples of each reaction taken at indicated timepoints. NF-kB activity was measured as a fold induction of SEAP in the supernatant and cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 31 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (20, 10, 5, 2.5, 1.25, 0.625 pM) followed by addition of IL36γ for 2 h at 37°. HeLaIL36R were stimulated for 24 h. IL-6 cytokine concentrations in culture supernatants were determined by ELISA. Note: b-FLF, FLF, GLF, KAL, AFLF, EPF peptides and CatG I-1 serve as negative controls for IL-36γ assay. -
FIG. 32 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (200, 100, 50, 25, 12.5 μM) followed by addition of IL36γ for 2 h at 37°. HeLaIL36R were stimulated for 24 h. IL-6 cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 33 are graphs showing Neutrophils degranulates pre-incubated for 30 min on ice in the presence or absence of a titration of peptide (200, 100, 50, 25, 12.5 μM) followed by addition of IL36β for 2 h at 37°. HeLaIL36R were stimulated for 24 h. IL-6 cytokine concentrations in culture supernatants were determined by ELISA. Note: AAPV, API, ARPV, DTEF, RPI, RPL, APL, APV, PQR, RAV, and RPV peptides serve as negative controls for IL-36β assay. -
FIG. 34 (A) is a Coomassie blue stained gel of recombinant IL-36β that was incubated with a titration of purified cathepsin K. Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as (6EAAP). (B) is schematics representing NPQR5 cleavage motif within IL-36β and the point mutant IL-36β RSA. -
FIG. 35 (A) are graphs showing HeLaIL-36R stimulated with recombinant IL-36β and IL-36βR5A (625 μM) incubated with indicated concentrations of cathepsin K. After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 36 is the complete DNA coding sequence (SEQ ID No. 3) and corresponding amino acid sequence (SEQ ID No. 4) for the IL-36β gene (Homo sapiensinterleukin 1 family, member 8 (eta), mRNA (cDNA clone MGC:126882 IMAGE:8069339), complete cds) -
FIG. 37 is the complete DNA coding sequence (SEQ ID No. 5) and corresponding amino acid sequence (SEQ ID No. 6) for the IL-36γ gene (Homo sapiensinterleukin 1 family,member 9, mRNA (cDNA clone MGC:119102 IMAGE:40003612), complete cds) -
FIG. 38 is the complete DNA coding sequence (SEQ ID No. 26) and corresponding amino acid sequence (SEQ ID No. 27) for the IL-36α gene (Homo sapiensinterleukin 1 family,member 6, mRNA (cDNA clone MGC:129553 IMAGE:40002576), complete cds) -
FIG. 39 (A) is a Coomassie blue stained gel of recombinant IL-36α that was incubated with a titration of purified cathepsin-G and elastase. Indicated fragment was analysed by Edman Degradation sequencing and novel N-terminus was identified as (4ALKI) for cathepsin-G and (5LKID) elastase, respectively. (B) is a schematic representing cathepsin-G and elastase cleavage motifs within IL-36α. -
FIG. 40 (A and B) are graphs showing control and psoriatic skin elutes that were assessed for Cathepsin G activity by FLF-sBzl hydrolysis assay (A) or Elastase activity (B). (C) is a graph showing HeLaIL36R cells incubated with equal concentrations of IL-36α, β, γ cytokines (500 μM) that had been pre-incubated for 2 h at 37° with either control or psoriatic skin elutes in the presence or absence of either cathepsin G inhibitor 1 (10 μM) or elastase inhibitor IV (10 μM). IL-8 cytokine concentrations in culture supernatants were determined by ELISA. -
FIG. 41 (A) are graphs showing HeLaIL-36R stimulated with recombinant IL-36β and IL-36βR5A (500 μM) incubated with indicated concentrations of proteinase-3 (B) are pM) incubated with indicated concentrations of proteinase-3. After 24 hr, cytokine concentrations in culture supernatants were determined by ELISA. - Polyclonal antibodies were generated against IL-36 α, β and γ by repeated immunization of rabbits with the full-length recombinant IL-36 proteins (Biogenes, Germany). anti-IL-1α and anti-IL-1β were purchased from R&D systems (UK). anti-Actin (clone C4) was from MP Biomedicals, anti-Bax (clone 6A7) was from Sigma, anti-Cullin-3 was from BD antibodies. Synthetic peptides, Ac-DEVD-AMC (SEQ ID No. 9), Ac-WEND-AMC (SEQ ID No. 10), and biotin-VAD-FMK were all purchased from Bachem (Germany); Suc(oMe)-AAPV-AMC (SEQ ID No. 11) was purchased from Peptanova (Germany); biotin-VAD-FMK was purchased from ICN (UK). Novel synthetic peptides biotin-FLF-CMK, z-FLF-CMK, z-AFLF-CMK, z-EPF-CMK, z-GLF-CMK, z-KAL-CMK, z-GLK-CMK and z-GLW-CMK were synthesised by Boston Open Labs (USA). Chemical inhibitors Cathepsin G Inhibitor I and Elastase Inhibitor IV were purchased from Calbiochem (UK). Purified Neutrophil-derived Cathepsin G was purchased from Calbiochem (UK). Purified Neutrophil-derived Elastase was purchased from Serva (Germany). Unless otherwise indicated, all other reagents were purchased from Sigma (Ireland) Ltd.
- Full-length poly-histidine-tagged IL-36α, β and γ proteins was generated by cloning the human coding sequence in frame with the poly-histidine tag sequence in the bacterial expression vector pET45b. Protein was expressed by addition of 600 pM IPTG to exponentially growing cultures of BL21 strain E. coli followed by incubation for 3 h at 37° C. Bacteria were lysed by sonication and poly-histidine tagged proteins were captured using nickel-NTA agarose (Qiagen, UK), followed by elution into PBS, pH 7.2, in the presence of 100 mM imidazole. Modified forms of IL-36 where cloned that included a caspase-3-processing motif (DEVD) into the IL-36 sequences, N-terminal to the known processing sites22. All IL-36 mutants were expressed and purified in the same way. Recombinant poly-histidine-tagged caspases-1, and -3, were also expressed and purified as described above.
- Site-directed mutagenesis was carried out using the QuikChange kit (Stratagene). Mutagenesis of IL-36 genes was verified by sequencing (Eurofins MWG Operon).
- In vitro transcription/translation reactions were carried out using purified plasmid templates added to a rabbit reticulocyte lysate system (Promega, UK).
- To precipitate protein from supernatant, TCA was added at a 1:4 ratio to supernatant volume (250 μl to 1 ml supernatant) and incubated on rotation for 10 min. Supernatants were centrifuged at 15,000 g for 10 min. Top layer was removed without disturbing the pellet. 200 μl pre-chilled acetone was added to each pellet and mixed by several inversions. Samples were centrigued for a further 10 min at 15,000 g. Samples were then put on heating block to burn off the acetone. 1×SDS-PAGE loading buffer (Tris.Cl, 50 mM, SDS, 2%, Glycerol 10%, Bromophenol Blue, 0.05%, β-mercaptoethanol, 2.5%) was added to each sample pellet. Samples were then boiled for a further 5 mins. Cell lysates were prepared using SDS-PAGE loading buffer and were electrophoresed on 8-13% SDS-polyacrylamide gels followed by transfer onto nitrocellulose membranes. Protein expression was subsequently examined by immunoblotting with the appropriate antibodies.
- Primary neutrophils were purified from donor human blood using the plasma-Percoll gradient method. Purity of cell preparations (>90%) was determined by Hematoxylin and Eosin staining of cytospins. To prepare degranulates, neutrophils (107 per treatment) were stimulated in the presence or absence of 50 nM PMA in HBSS/0.25% BSA for 1-3 h at 37° C. in a humidified atmosphere with 5% CO2. Supernatants were harvested and clarified by centrifugation. Degranulate aliquots were stored at −80°.
- Reactions (50 μl final volume) were carried out in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS/2 mM DTT) containing 50 pM Ac-DEVD-AFC, Ac-WEND-AMC, Suc(oMe)-AAPV-AMC. Samples were measured by using an automated fluorimeter (Spectrafluor Plus; TECAN) at wavelengths of 430 nm (excitation) and 535 nm (emission). For suc-FLF-sBzl assay, substrate was diluted to a final concentration of 300 pM in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS/
DTNB 300 μM). Samples were measured by automated fluorimeter (Spectrafluor Plus; TECAN) at an absorbance wavelength of 430 nM. - Reactions (40-100 μl final volume) were carried out in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS) for 2 h at 37°.
- Cytokines and chemokines were measured from cell culture supernatants using specific ELISA kits obtained from R&D systems (human IL-6, IL-8, CXCL1, MCP-1, IL-17C). Each assay was repeated a minimum of three times and all cytokine assays were carried out using triplicate samples from each culture.
- HeLa were cultured in RPMI media (Gibco), supplemented with 5% fetal calf serum (FCS). HaCat were cultured in DMEM (Gibco) supplemented with FCS (10%). Primary neonatal foreskin derived Keratinocytes P0 were purchased from Cell Systems (Germany) and cultured in serum-free Dermalife K media (Cell Systems, Germany). HeLa.vector or HeLa.IL-36R cell lines were generated by transfection with pCDNA3 or pCDNA3.IL-1rrp2 followed by selection using G-418 antibiotic (Sigma). IL-1rrp2 over-expressing clones were confirmed by immunoblotting and the final clone selected by demonstration of acquired responsiveness to active forms of IL-36. All cells were cultured at 37° C. in a humidified atmosphere with 5% CO2.
- Skin Models were Generated Using 24 Well Inserts (Nunclon™ Δ, Nunc, Rochester, N.Y.) in 24 well plates (Greiner-bio-one). Per
insert 1×105 fibroblasts in GNL (322.5ml 2×DMEM; 7.5 ml 3 M HEPES; 1.25 ml chondroitin-4-sulfate; 1.25 ml chondroitin-6-sulfate; 7.5 ml FCS) were mixed 1:3 with collagen I isolated from rat tails to a final volume of 500 μl and cultivated in DMEM/4.5 g/l glucose/1% L-glutamine/10% FCS/-L-pyruvate over night at 37° C. Next day dermal gels were equilibrated with EGM/10% FCS/1% PenStrep/10 mg/ml gentamycine for 2 h at 37° C. The medium was withdrawn and 1×105 keratinocytes in EGM carefully seeded on top and incubated for 1.5 h at 37° C. to allow adhesion. Subsequently, skin equivalent were covered with EGM and cultivated for 7 days—changing the medium every other day. Atday 7 skin equivalents were transferred to 6 well plates and cultivated/treated at the air-liquid interface in MM for 15 more days at 37° C., changing the medium every other day. Skin reconstructs were fixed in Roti-Histofix (Roth; Karlsruhe, Germany) for 3 h at RT released from the insert and embedded into paraffin. Sections of 3 μm were cut using a RM 2145-microtome (Leica, Biberach, Germany), transferred onto slides (LABOnord; Greiner-bio-one) for hematoxylin-eosin (HE)-staining or onto sialynized slides (Menzel GmbH, Braunschweig, Germany) for immunhistochemical analysis and dried at 37° C. over night. Sections were released from paraffin using Roticlear (Roth) and subjected to HE-staining at RT or were incubated with primary antibodies against keratin 10 (Dako, Hamburg, Germany),keratin 14, filaggrin (Biomedia, Singapore) and involucrin (Acris, Herford, Germany), respectively, as recommended by the manufacturer at 4° C. over night. Secondary polyclonal goat-anti-mouse-FITC (Dako) or goat-anti-mouse-Cy3 IgG (Jackson ImmunoResearch) antibodies were used, slides mounted in ProLong® Gold with or without DAPI (MolecularProbes® life technologies™) and analyzed using an Apotom1-Axio Imager and CEN software (Zeiss). - Primary human neonatal foreskin-derived Keratinocytes (P3) were used for gene expression analysis. Primary Keratinocytes were stimulated with IL-36β for 8 and 24 h timepoints. Cells were harvested with RNAprotect cell reagent (Qiagen) and stored at −80°. Analysis of samples were performed using SurePrint G3 Human Gene Expression 8x60K v2 Microarray using a one-color based hybridization protocol and preformed by IMGM Laboratories (Germany).
- RNA was extracted from cells using the RNeasy Kit (Qiagen) as per manufacturer's instructions. cDNA was generated using the Omniscript RT Kit (Qiagen) and used to seed RT-PCR reactions (LightCycler® FastStart DNA Master Mix Sybr Green I). Quantification of cytokine gene products was preformed using the Roche Light Cycler 1.5 software and normalized to the β-Actin housekeeping gene.
-
Primers for RT-PCR Primer sequence design for cytokine gene expression by real-time RT-PCR. IL-17C Forward (SEQ ID No. 12) 5′ TTG GAG GCA GAC ACC CAC C 3′, IL-17C Reverse (SEQ ID No. 13) 5′ GAT AGC GGT CCT CAT CCG TG 3′ IL-36γ Forward (SEQ ID No. 14) 5′ GAA ACC CTT CCT TTT CTA CCG TG 3′ IL-36γ Reverse (SEQ ID No. 15) 5′ GCT GGT CTC TCT TGG AGG AG 3′ IL-8 Forward (SEQ ID No. 16) 5′ TCTGCAGCTCTGTGTGAAGG 3′ IL-8 Reverse (SEQ ID No. 17) 5′ ACT TCT CCA CAA CCC TCT GA 3′ G-CSF Forward (SEQ ID No. 18) 5′ GCT TAG AGC AAG TGA GGA AG 3′ G-CSF Reverse (SEQ ID No. 19) 5′ AGG TGG CGT AGA ACG CGG TA 3′ GM-CSF Forward (SEQ ID No. 20) 5′ GAG CAT GTG AAT GCC ATC CAG GAG 3′ GM-CSF Reverse (SEQ ID No. 21) 5′ CTC CTG GAC TGG CTC CCA GCA GTC AAA 3′ β-defensin-2 Forward (SEQ ID No. 22) 5′ ATG AGG GTC TTG TAT CTC CT 3′ β-defensin-2 Reverse (SEQ ID No. 23) 5′ TAT CTT TGG ACA CCA TAG TT 3′ β-Actin Forward (SEQ ID No. 24) 5′ ATG TTT GAG ACC TTC AAO AC 3′ β-Actin Reverse (SEQ ID No. 25) 5′ CAC GTC ACA CTT CAT GAT GG 3′ - 4 mm punch biopsies were obtained from 3 individuals presenting with clinical features of psoriais. The punch biopsies were obtained from uninvolved as well as involved areas of epidermis. Samples were homogenized using a dounce homogenizer in protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS. 1×SDS-PAGE loading buffer (Tris.Cl, 50 mM, SDS, 2%, Glycerol 10%, Bromophenol Blue, 0.05%, β-mercaptoethanol, 2.5%) was added to each sample pellet. Samples were then boiled for a further 5 mins. Cell lysates were prepared using SDS-PAGE loading buffer and were electrophoresed on 8-13% SDS-polyacrylamide gels followed by transfer onto nitrocellulose membranes. Protein expression was subsequently examined by immunoblotting with the appropriate antibodies.
- Tape-Strip Samples from Control and Psoriatic Skin
- Fixomull (2 cm×2 cm) adhesive tape strips were applied to a healthy or psoriatic skin, under firm pressue for 10 seconds. The tape-strip was placed in sterile 1.5 ml eppendorfs and eluated with protease reaction buffer (50 mM Hepes, pH 7.4/75 mM NaCl/0.1% CHAPS) under constant rotation for 1 h at 4° c. Sample eluates were stored at −80° C. Enzymatic assays and bioassays were setup using control and psoriatic eluates as described above.
- To identify whether IL-36 isoforms are proteolytically processed and activated by a particular protease, IL-36 is incubated with the protease for approximately 2 hours at 37° C. The reaction is then added to a cell line and the biological activity of the IL-36 protein is determined by the ability of IL-36 receptor (IL-36R) expressing cells, such as HeLa cells, Primary Keratinocytes, HaCat cells, to secrete factors into the cell culture medium. These secreted factors are quantified by ELISA (as shown in for example,
FIG. 4B ,FIG. 7 ,FIG. 8 ,FIG. 16 ,FIG. 17 ,FIG. 21A ). - To determine the proteolytic cleavage site(s) that activate IL-36, the protease is incubated with IL-36 for approximately 2 hours at 37° C., and the resulting reaction is analyzed by gel electrophoresis using an SDS-PAGE gel to separate denatured protein by the length of the polypeptide. The SDS-PAGE gel is then transferred onto PDVF membrane. This embeds the protein content of the SDS-PAGE gel onto the PVDF membrane. The PDVF membrane is stained with Coomassie blue. This dye stains the protein content of the PDVF and resolves the IL-36 protein and any cleavage bands are also made visible. These cleavage bands are subsequently excised and analysed by conventional Edman degradation sequencing to determine what is the N-terminus amino acid for the particular cleavage band that has been analysed. This is shown in, for example, IL-36α (see
FIG. 39 ), IL-36β (seeFIG. 9-12 ,FIG. 34 ) and IL-36γ (seeFIG. 13-15 ). - Once this has been determined, this enables the particular residue(s) to be mutated via site-directed mutagenesis, whereby the cleavage site residue is changed to some other amino acids, typically a Glycine (Gly) or Alanine (Ala) (
FIG. 9-12 ,FIG. 13-15 ,FIG. 39 ). The proteolytic reaction is now repeated using this mutant version of IL-36 (whereby the cleavage site has to be changed) with the protease. Again, this is shownFIG. 9-12 ,FIG. 13-15 ,FIG. 34 ,FIG. 39 , whereby point mutants within IL-36 block activation by either cathepsin-G, Elastase, proteinease-3 or cathepsin K. - Based on the cleavage sites identified within the IL-36 isoforms, peptides, including tri-/tetra-peptides, can be designed that mimic these cleavage motifs using conventional techniques.
- Typically, a tri-/tetra-peptide will encompass the residues upstream and downstream of the cleavage site. The general nomenclature of cleavage site positions of the substrate were formulated by Schechter and Berger32-33. They designate the cleavage site between P1-P1′, incrementing the numbering in the N-terminal direction of the cleaved peptide bond (P2, P3, P4, etc.). On the carboxyl side of the cleavage site the numbering is incremented in the same way (P1′, P2′, P3′ etc.).
- This has enabled the design and synthesis of suitable peptide. For example, RAV peptide (
FIG. 32 , second row) mimics the cleavage site of IL-36α GRAV15, (G-R-A-V-P1′-P2′-P3′). Additionally, KAL peptide (FIG. 28 , second row) mimics the cleavage site of IL-36α MEK3AL, (M-E-K-P1′-P2′-P3′) by cathepsin-G and the cleavage site of IL-36c(MEKA4L, (M-E-K-A-P1′-P2′-P3′) by elastase. - It is standard practice to synthesize peptides that reproduce the P1, P2, P3 or P1, P2, P3 and P4 amino acid residues in the substrate cleavage motif (i.e. the region at which the protease cleaves the substrate) to mimic the substrate itself and therefore compete with the protease for access to the substrate. It is also standard practice to choose chemically similar peptides to those specified in the P1, P2, P3 or P1, P2, P3 and P4 amino acid residues of the substrate to generate alternative peptide mimetics that would achieve the same effect. Thornberry et al., (Thornberry N A, Bull H G, Calaycay J R, Chapman K T, Howard A D, Kostura M J, Miller D K, Molineaux S M, Weidner J R, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74) and Nicholson et al., (Nicholson D W, Ali A, Thornberry N A, Vaillancourt J P, Ding C K, Gallant M, Gareau Y, Griffin P R, Labelle M, Lazebnik Y A, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43) are examples of the approach.
- Design of Peptides that Binds an IL-36 Activating Protease or Activator Thereof for Use as Agents
- Based on the identification of the proteases responsible for activating IL-36 isoforms, peptides, including tri-/tetra-peptides, can be designed that bind these proteases using conventional techniques.
- As described above it is standard practice to synthesize peptide which target and/or inhibit a protease (e.g. Thornberry et al., (Thornberry N A, Bull H G, Calaycay J R, Chapman K T, Howard A D, Kostura M J, Miller D K, Molineaux S M, Weidner J R, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr. 30; 356(6372):768-74) and Nicholson et al., (Nicholson D W, Ali A, Thornberry N A, Vaillancourt J P, Ding C K, Gallant M, Gareau Y, Griffin P R, Labelle M, Lazebnik Y A, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul. 6; 376(6535):37-43)).
- In the most common strategy of solid phase peptide synthesis, as described by Merrifield (37), an amino acid with both α-amino group and side chain protection is immobilized to a resin. The α-amino-protecting group is usually an acid-sensitive tert-butoxycarbonyl (Boc) group or a base-sensitive 9-fluorenylmethyloxycarbonyl (Fmoc) group. These α-amino-protecting groups can be efficiently removed, and a protected amino acid with an activated carboxyl group can then be coupled to the unprotected resin-bound amine. The coupling reactions are forced to completion by using an excess of activated soluble amino acid. The cycle of deprotection and coupling is repeated to complete the sequence. With side chain deprotection and cleavage, the resin yields the desired peptide (36,37).
- For chloromethyl ketone (CMK)-modified peptides, the CMK chemical group located at the C-terminus of the peptide will occupy the active site but will form a covalent bond resulting in irreversible inhibition of the protease. More specifically, CMK are transition-state irreversible inhibitors. The active site Ser 195 of the enzyme forms a tetrahedral adduct with the carbonyl group of the inhibitor, and the active site histidine is alkylated by the CMK functional group (See REF:35)
- To identify the proteases responsible for processing and activation of IL-36 cytokines, we established an IL-36 bioassay by stably transfecting HeLa cells with the human IL-36 receptor (IL-1 Rrp2). Sims and colleagues have reported that artificial truncation of IL-36α, β and γ at particular N-terminal residues dramatically increases the activity of these proteins24 (
FIG. 1a ). To confirm that HeLaIL-36R cells were IL-36-responsive, we created modified forms of IL-36α, β and γ by inserting a caspase-3 cleavage motif, DEVD, proximal to the residues identified by Towne et al. to lead to IL-36-dependent NFkB activation when exposed at the N-termini of IL-36 cytokines (FIG. 1a ). AsFIG. 1b illustrates, DEVD-modified IL-36β (IL-36bDEVD) and DEVD-modified IL-36γ (IL-36gDEVD) was readily processed by caspase-3 whereas IL-36bwt and IL-36gwt were not. HeLawt cells failed to respond to either full length or caspase-3-cleaved IL-36βDEVD, while HeLaIL-36R cells secreted multiple cytokines in response to caspase-3-processed IL-36βDEVD but not full length unprocessed IL-36βDEVD (FIG. 2a, b ,FIG. 3 ). Similar data were obtained for a DEVD-modified form of IL-36α (FIG. 3a, b ). Furthermore, the transformed skin line HaCat, which naturally express IL-1Rrp2, also responded to the caspase-3-cleaved IL-36DEVD forms. (FIG. 3d ). These data confirmed that proteolytic processing of IL-36α, β and γ dramatically increase the biological activity of these cytokines and established a bioassay to screen for proteases that naturally process and activate IL-36 cytokines. - One of the hallmarks of psoriatic lesions is persistent infiltration of the epidermis by neutrophils23,29. Neutrophil granule proteases contain three major seine proteases (elastase, cathepsin G and proteinase-3) that are involved in bacterial killing as well as in the processing of certain cytokines and chemokines27. Indeed, previous studies have found that neutrophil elastase can process and activate IL-1α28 and that cathepsin G and elastase can activate IL-3329. To explore whether neutrophil-derived proteases can process and activate IL-36 cytokines, we induced human peripheral blood neutrophils to degranulate with PMA, thereby liberating granule proteases and generating reactive oxygen species (ROS)39-31 (
FIG. 4a, b ). Robust ROS production and protease activity was found in supernatants from PMA-treated neutrophils, as expected (FIG. 4b ). Purified full-length IL-36α, b and g were then incubated with supernatants from untreated versus PMA-treated neutrophils, followed by assessment of IL-36 activity using HeLaIL-36R cells. As shown inFIG. 4c , incubation of IL-36 cytokines in the presence of PMA-activated neutrophil degranulates resulted in robust activation of IL-36β and IL-36γ, whereas IL-36α was poorly activated under the same conditions. - To identify the specific protease(s) involved in IL-36β and γ activation, we initially used a panel of broad-spectrum protease inhibitors. As
FIG. 5 illustrate, the serine protease inhibitor PMSF, as well a specific chemical inhibitor of cathepsin G robustly inhibited the activation of IL-36α and IL-36β while a specific chemical inhibitor of elastase inhibited the activation of IL-36γ by activated neutrophil degranulates. To explore the identity of the IL-36 processing protease(s) further, we designed a panel of peptides based upon optimal cathepsin G cleavage motifs. These peptides were then assessed for their ability to inhibit activation of IL-36 cytokines by PMA-activated neutrophil degranulates. AsFIG. 6 ,FIG. 29 ,FIG. 30 demonstrate, the cathepsin G-inhibitory peptides, FLF-CMK, AFLF-CMK and EPF-CMK, proved to be the most potent inhibitors of IL-36β activation by neutrophil degranulates. In contrast, IL-36γ activation was antagonized by a specific chemical inhibitor of elastase (FIG. 6 ). We also generated a biotin-conjugated form of the cathepsin G inhibitor, biotin-FLF-CMK, to ask whether this depleted the IL-36b activating activity from neutrophil degranulates. AsFIG. 6a illustrates, selective depletion of cathepsin G activity from PMA-treated neutrophil degranulates using biotin-FLF-CMK largely eliminated activation of IL-36b but not of IL-36g (FIG. 6b ). - We next compared the ability of purified cathepsin G, elastase and proteinase-3 to process and activate IL-36 cytokines. The activity of all purified proteases employed was confirmed using synthetic substrate peptides (
FIG. 7a ). AsFIG. 7b demonstrates, cathepsin G selectively promoted IL-36β activation, whereas elastase and proteinase-3 preferentially activated IL-36γ. Furthermore, IL-36α is activated by cathepsin-G and proteinase-3 (FIG. 7b ). Because caspase-1 processes and activates the IL-1 family cytokines, IL-1β and IL-18, we also explored whether caspase-1 or caspase-3 could process and activate IL-36 family cytokines. However, asFIG. 7b illustrates, neither caspase activated any of the IL-36 cytokines. To exclude the possibility that the concentrations of IL-36α we used in the above experiments were too low to detect biological activity, we also titrated IL-36 cytokines over a wide concentration range in the presence and absence of cathepsin G, elastase or proteinase-3. AsFIG. 8 shows, once again cathepsin G was found to preferentially activate IL-36β and to some extent proteinase-3 while elastase and proteinase-3 preferentially activate IL-36γ. Cathepsin G also exhibiting modest activation of IL-36γ at higher molar concentrations. Finally, all three neutrophils proteases activate IL-36α at higher molar concentrations (FIG. 8 ). - To identify the cathepsin G cleavage site(s) within IL-36β that result in activation, we performed N-terminal sequencing of cathepsin G-treated IL-36β preparations. This analysis identified two candidate sites at Arg5 and Phe53 (
FIG. 9 ). Thus, we generated mutations at both of these sites to assess their role in cathepsin G-mediated activation of IL-36β. We initially tested each mutant for resistance to proteolysis by cathepsin G. AsFIG. 10 shows, IL-36βF53A suppresses appearance of the two major cleavage bands (˜10 and ˜4 kDa), yet still generates a third cleavage band (˜17 kDa) just below the full-length protein. In contrast, IL-36βR5A largely attenuates the appearance of the ˜17 kDa band just below the full-length band while the appearance of the cleavage bands (˜10 and ˜4 kDa) are significantly diminished. AsFIG. 11 ,FIG. 12 illustrate, whereas mutation of Phe53 had no effect on cathepsin G-mediated IL-36β activation, mutation of Arg5 dramatically abolished activation of this cytokine. Furthermore, mutation of Arg5 also abolished activation of IL-36β by PMA-activated neutrophil degranulates (FIG. 11 ,FIG. 12 ). Using a similar approach, we identified Val15 in IL-36γ as the residue cleaved by elastase to promote activation of the latter (FIG. 13 ). Mutation of this residue also significantly attenuated activation of the latter by elastase, as well as by PMA-activated neutrophil degranulates (FIG. 14 ,FIG. 15 ). - To explore the biological activity of IL-36β in a physiologically relevant cell type, we used transformed HaCat keratinocytes as well as primary human epidermal keratinocytes to ask whether cathepsin G-processed IL-36β or elastase-processed IL-36γ were capable of triggering the production of pro-inflammatory cytokines from these cells. As illustrated in
FIG. 16 , whereas full length IL-36β or IL-36γ exhibited little activity on HaCaT cells, cathepsin G-treated IL-36β and elastase-processed IL-36γ induced robust production of chemokines from these cells. Essentially identical results were seen with primary human keratinocytes (FIG. 17 ). Furthermore, using a reconstituted human 3D skin model, we also found that cathepsin G-processed IL-36β was sufficient to perturb skin differentiation to produce features resembling psoriasis, such as acanthosis and marked hyperkeratosis of the cornified layer (FIG. 18 ). - To explore the biological effects of IL-36 further, we conducted gene expression array analyses in primary keratinocytes. As
FIG. 19 demonstrates, cathepsin G-activated IL-36β induced robust expression of a diverse array of pro-inflammatory cytokines and chemokines from these cells. Of particular note, IL-36 induced strong transcriptional upregulation of IL-17C (˜50-fold within 8 hours), a cytokine that has been implicated as a key driver of the pathology observed in psoriasis and other conditions. IL-36β also induced robust expression of multiple additional inflammatory factors, such as complement C3, b-defensin-2, S100A9, TNFα, and G-CSF which are frequently elevated in lesional skin from psoriatic patients19 (FIG. 19 ). Interestingly, we also found that IL-36γ induced a strong signature of IL-36γ upregulation in primary keratinocytes, suggesting that this cytokine can promote a positive feedback loop for IL-36 cytokine expression. We validated IL-36-induced expression of several of these cytokines at the mRNA level (FIG. 20 ), as well as by ELISA, including IL-8, CXCL1 and IL-17C (FIG. 21a, b ). Furthermore, IL-17C can itself promote cytokine production from primary keratinocytes (FIG. 21c ). - To explore the expression of endogenous IL-36 cytokines in keratinocytes, we generated polyclonal antibodies against all three IL-36 cytokines (
FIG. 22 ). Whereas little endogenous IL-36α or β could be detected constitutively, IL-36γ was detected in primary keratinocytes (FIG. 22a ). However, treatment of these cells with IL-36, PMA or the Toll-3 agonist poly:(IC) robustly induced the expression of endogenous IL-36γ (FIG. 23a, b ). HaCat were also found to upregulate IL-36γ after IL-36 and PMA treatment (FIG. 24a, b ). Primary human keratinocytes are reported to express the full-length forms of pro-IL-1α and pro-IL-1β at the protein level25. Indeed, we detected both, pro-IL-1α and pro-IL-1β constitutively expressed in primary keratinocytes (FIG. 22a, b ). Furthermore, these cytokines were upregulated further in response to IL-36 and Poly:(IC) (FIG. 22a, b ). Similar observations were made with HaCat cells (24 a, b). - Consistent with previous data on other IL-1 family members IL-1β and IL-18, we failed to detect IL-36-dependent activity in the supernatants of SLO-lysed keratinocytes containing full-length IL-36γ (
FIG. 7a, b ). Of particular note, we also observed release of the full-length forms of IL-1α and IL-1β along with release of irrelevant proteins Cullin-3 and Actin into the cell supernatants, indicative of the non-selective nature of necrotic cell death (FIG. 7a ). Furthermore, supernatants from SLO-lysed keratinocytes cells displayed activity that was IL-36-independent, but was dependent on IL-1α (FIG. 25a, b ). To explore if IL-36γ, both intracellularly and extracellularly is subject to cleavage by neutrophil elastase, we generated cell extracts and supernatants followed by incubation with neutrophil proteases. AsFIG. 26 a, b, illustrates, IL-36γ incubated with elastase resulted in robust IL-36γ proteolysis both intracellularly as well as extracellularly, with the resulting cleavage fragments running at a similar mobility to that produced through proteolysis of recombinant IL-36γ by elastase. Collectively these data indicate a role for IL-36 cytokines as targets of neutrophil serine proteases. - IL-36γ is Greatly Elevated within Lesional Skin from Psoriatic Individuals
- To explore whether IL-36 ligands was elevated in lesional skin from psoriatic individuals, we generated homogenates from skin samples obtained from uninvolved as well as involved areas from psoriatic individuals. As
FIG. 27a shows, these experiments revealed that IL-36g was greatly elevated in psoriatic tissue, while IL-36α and IL-36β were undetectable in these patient samples. Furthermore, incubating these psoriatic homogenates with neutrophil elastase resulted in IL-36γ proteolysis, with the resulting cleavage fragments running at a similar mobility to that produced through proteolysis of recombinant IL-36γ (FIG. 27b ). - Psoriatic Lesional Skin Displays a Predominantly Cathepsin-G Like Activity that Activates IL-36 Cytokines
- To explore the role of neutrophil proteases in a disease relevant setting, we generated control skin and psoriatic skin samples via the tape-strip method. As
FIG. 40a, b show, these experiments revealed that psoriatic skin eluates contains a significantly elevated cathepsin-G like protease activity as demonstrated by robust FLF-sBzl hydrolysis, while Elastase-like activity was not elevated in psoriatic skin measured using the AAPV-AMC peptide. Next, we incubated these control and psoriatic skin eluates with equal molar concentrations of IL-36 cytokines. AsFIG. 40c demonstrates, IL-36β was robustly activated by psoriatic skin eluates, with IL-36α activated but to much less efficient degree. Control skin eluates failed to activate IL-36 cytokines. Consistent with the cathepsin-G-like enzymatic activity, a specific cathepsin-G inhibitor attenuated IL-36β and IL-36α activation by the psoriatic skin eluates, while an elastase inhibitor failed to attenuate IL-36 activation. These data, are consistent with a cathepsin-G like enzymatic activity in psoriatic skin that is capable of activating IL-36β. - Our findings show that IL-36 cytokines are activated by neutrophil granule proteases. In particular, IL-36β and IL36γ are processed by cathepsin G,elastase and proteinase-3, respectively and proteolysis of these cytokines releases their full biological potency. Previous reports by Sims and colleagues24 suggested that IL-36 cytokines have limited biological activity as full-length proteins, and require processing at their N-termini to activate them. However, the latter authors did not identify the proteases that naturally process and activate these cytokines, but mapped their active forms using artificial truncations. We have also found that IL-36 cytokines have very limited biological activity as full-length proteins, however proteolysis by cathepsin G,elastase and proteinase-3 greatly enhanced the biological activity of IL-36β and IL-36γ respectively.
- Proteolysis of IL-36 cytokines may induce a profound conformational change in these proteins that increase their affinity for the IL-36 receptor (IL-1 Rrp2), thereby increasing biological potency. Alternatively, the IL-36 N-termini may partly occlude the receptor binding domain, removal of which permits a more stable interaction with the IL-36R complex. Previously, Hazuda and colleagues have reported that pro-IL-1α and pro-IL-1β cytokines undergo profound conformational changes upon removal of their N-termini and, as a consequence, the mature regions of these molecules switch from a proteinase K-sensitive to a proteinase K-insensitive state. This change is most likely reflected in an altered conformation that increase their affinity for the IL-1 receptor26.
- Immune cell infiltration is a hallmark of a number of skin-related inflammatory diseases. In particular, psoriatic plaques are heavily infiltrated with neutrophils, dendritic cells, macrophages, and T-cells26. Neutrophils are critical first responder cells in our innate immune system and play a critical role in the initial response to infection or tissue damage. Neutrophils perform a range of functions in their role in immune defence and inflammation which includes: engulfment and destruction of microbes via ROS production, release of neutrophil extracellular traps to sequester and kill microbes, release of cytokines to orchestrate immune responses, as well as the production of a vast repertoire of antimicrobial molecules such as defensins, and granule proteases such as elastase and cathepsin G27. Furthermore, mice doubly deficient in the neutrophil granule proteases cathepsin G and elastase have deficiencies in bacterial clearance as well as increased mortality to streptococcus, pseudomonas, and mycobacterial infections28-28. While the degranulation and release of neutrophil proteases exert profound antimicrobial and protective effects during infection, in excess they can cause extensive tissue damage through ROS production, inflammatory cytokine activation, as described herein, and protease degradation of the extracellular matrix31. Excessive neutrophil protease activity is typically prevented by serum anti-proteases such as α-1-antitrypsin and 2-macroglobulin that are also typically synthesized during inflammatory responses27.
- Interestingly, the onset of psoriasis symptoms in affected individuals often follows a streptococcal A infection, which is likely to be associated with both necrosis of infected, as well as surrounding tissue and with robust neutrophil and macrophage infiltration. If necrosis is not a direct consequence of pathogen activities, necrosis of barrier tissues as a result of compression injuries or burns, for example, is likely to lead to infection. Thus, the immune system recognizes this as potential danger and mounts an innate immune response characterized by the infiltration immune cells such as neutrophils and macrophages into the site of injury9,30. Curiously, clinicians have observed that the development of psoriatic lesions can develop as a result of the epidermis experiencing physical injuries such as lacerations, burns or after surgical incisions. This trauma-induced psoriasis is often described as the ‘Koebner phenomenon’, which was first described in 187735. An important feature that unites all of the above diverse scenarios is that all are capable of triggering necrotic cell death in the epidermis. As a direct consequence of necrosis, non-classical cytokines such as IL-36, IL-33 and IL-1α are released into the extracellular space where they can act on local epithelia to drive further inflammation. Necrosis can also lead to robust activation and infiltration of the injured site by cells of the immune systems such as neutrophils, macrophages and mast cells. It is under these conditions that extracellular IL-36 ligands may encounter and become processed by neutrophil serine proteases as these proteases are frequently found at elevated levels within psoriatic lesions. Indeed, our results show that activated IL-36 is capable of driving a robust inflammatory response in primary keratinocytes, including the induction of IL-1α, TNFα, IL-17C, G-CSF, IL-8, S100 proteins, as well as IL-36 itself. Keratinocytes make up the majority of cells within the epidermis, which constitutes a very important barrier against infection. In addition to serving as a physical barrier against the entry of microorganisms, it is now well appreciated that keratinocytes are capable of directly responding to damage or infection by releasing a number of key cytokines, such as IL-1α, IL-1β and IL-36 cytokines to activate local macrophages and dendritic cells to initiate immune responses5. In this respect keratinocytes serve as key sentinel cells that alert the immune system to potential danger. Moreover, our results show that IL-36γ as well as IL-1α/β, are endogenously expressed by keratinocytes and subject to modulation by either IL-36 signalling or Toll-receptor engagement. Therefore, keratinocytes are posed to release cytokines such as IL-36γ and IL-1α upon tissue injury. Thus, damage to keratinocytes, either as a result of microbial infection or through tissue trauma, is likely to play an important initiating role in psoriasis, especially in individuals carrying genetic predispositions to this disease (such as deficiency in the IL-36R antagonist). This leads to the triggering of an inflammatory reaction, of which IL-36 cytokines play a critical role, leading to further amplification of damage in a self-sustaining inflammatory loop.
- In summary, we have shown that IL-36 cytokines are robustly activated by the neutrophil proteases, cathepsin G,elastase and proteinase-3, as well as cathepsin K, and that this proteolysis increases their biological activity ˜500-fold. Collectively these results show an important role for neutrophil proteases as potent activators of IL-36 cytokines and suggest that targeted inhibition of these proteases, as described here, may have therapeutic benefits in inflammatory skin conditions such as psoriasis and other similar conditions.
- The invention is not limited to the embodiment(s) described herein but can be amended or modified without departing from the scope of the present invention.
-
- 1. Marrakchi, S., Guigue, P., Renshaw, B. R., Puel, A., Pei, X. Y., Fraitag, S., Zribi, J., Bal, E., Cluzeau, C., Chrabieh, M., Towne, J. E., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620-8 (2011)
- 2. Jesus, A. A., Goldbach-Mansky, R. IL-1 Blockade in Autoinflammtory syndromes Annu. Rev. Med. 65, 223-44 (2014)
- 3. Gottlieb, A. B Psoriasis: emerging therapeutic strategies Nat.
Rev. Drug Discov 4, 19-34 (2005) - 4. Lowes, M. A., Bowcock, A. M., Kruger, J. G. Pathogenesis and therapy of psoriasis Nature. 445, 866-873 (2007)
- 5. Pasparakis, M., Haase, I., Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289-301 (2014)
- 6. Taylor, P. C., Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 578-82 (2009)
- 7. Chaudhari, U., Romano, P., Mulcahy, L. D, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. LANCET 357, 1842-1847 (2001)
- 8. Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., Krueger, J. G. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34, 174-81 (2013)
- 9. Kono, H., and Rock, K. L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-89 (2008)
- 10. Sims, J. E., Smith, D. E., The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 2, 89-102 (2010)
- 11. Lukens, J. R., Gross, J. M., Kanneganti, T. D. IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol. 3, 315 (2012).
- 12. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Ann. Rev. Immunol. 27, 519-550 (2009)
- 13. Vigne, S., Palmer, G., Lammacchia, C., Martin, P., Talabot-Ayer, D., Rodriguez, E., Ronchi, F., Sallusto, F., Dinh, H., Sims, J. E., Gabay, C. IL-36R ligands are potent regulators of dendritic and T-cells. Blood 118, 5813-23 (2011)
- 14. Milovanovic, M., Volarevic, V., Radosavljevic, G., Jovanovic, I., Pejnovic, N., Arsenijevic, N., Lukic, M. L. IL-33/ST2 axis in inflammation and immunopathology.
Immunologic Research 52, 89-99 (2012) - 15. Towne, J. E., Sims, J. E. IL-36 in psoriasis. Curr. Opin. Pharmacol. 4, 486-90 (2012)
- 16. Farooq, M., Nakai, H., Fujimoto, A., Fujikawa, H., Matsuyama, A., Kariya, N., Aizawa, A., Fujiwara, H., Ito, M., Shimomura, Y. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum. Mutat. 34, 176-183 (2013)
- 17. Onoufriadis, A., Simpson, M. A., Pink, A. E., DiMeglio, P., Smith, C. H., Pullabhatla, V., Knight, J., Spain, S. L., Nestle, F. O., Burden, A. D., Capon, F., Trembath, R. C., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89, 432-437 (2011)
- 18. Kanazawa, N., Nakamura, T., Mikita, N., Furukawa, F. Novel IL-36RN mutation in a japanease case of early onset generalized pustular psoriasis. J Dermatol. 9, 749-51 (2013)
- 19. Johnston, A., Xing, X., Guzman, A. M., Riblett, M., Loyd, C. M., Ward, N. L., Wohn, C., Prens, E. P., Wang, F., Maier, L. E., Kang, S., Voorhees, J. J., Elder, J. T., Gudjonsson J. E. IL-1F5, -F6, -F8, -F9: a novel family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186, 2613-22 (2011)
- 20. Blumberg, H., Dinh, H., Trueblood, E. S., Pretorius, J., Kugler, D., Weng, N., Kanaly, S. T., Towne, J. E., Willis, C. R., Keuchle, M. K., Sims, J. E., Peschon, J. J. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204, 2603-14 (2007)
- 21. Blumberg, H., Dinh, H., Dean, C. Jr., Trueblood, E. S., Bailey, K., Shows, D., Bhangavathula, N., Aslam, M. N., Varani, J., Towne, J. E., Sims, J. E. IL-1 RL2 and its ligands contribute to the cytokine network in psoriasis. J. Immuno. 185, 4354-62 (2010)
- 22. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A. J., Renauld, J. C., Werner, S., Kisielow, J., Kofp, M. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin. Invest. 122, 3965-76 (2012)
- 23. Wu J K, Siller G, Strutton G. (2004). Psoriasis induced by topical imiquimod. Aust, J. Dermatol. 45, 47-50
- 24. Towne, J. E, Renshaw, B. R., Douangpanya, J., Lipsky, B. P., Shen, M., Gabel, C. A., Sims, J. E. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36b, IL-36g) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594-602 (2011)
- 25. Hazuda, D, J., Strickler, J., Simon, P., Young, P. R. Structure-function mapping of
interleukin 1 precursors. Cleavage leads to a conformational change in the mature protein. J. Biol. Chen. 266, 7081-7086 (1991) - 26. Frank, O., Nestle, M. D., Daniel, H., Kaplan, M. D., Barker, M. D. Psoriasis. N. Engl. J. Med. 361, 496-508 (2009)
- 27. Koloaczakowska, E., Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159-75 (2013)
- 28. Hahn, I., Klaus, A., Janze, A. K., Steinwede, K., Ding, N., Bohling, J., Brumshagen, C., Serrano, H., Gauthier, F., Paton, J. C., Welte, T., Maus, U. A. Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-protective immunity against Streptococcus pneumoniae in mice. Infect.
Immun.l 12, 4893-901 (2011) - 29. Steinwede, K., Maus, R., Bohling, J., Voedisch, S., Braun, A., Ochs, M., Schmiedl, A., Langer, F., Gauthier, F., Roes, J., Welte, T., Bange, F. C., Niederweis, M., Buhling, F., Maus, U. A. Cathepsin G and neutrophil elastase contribute to lung-protective immunity against mycobacterial infections in mice. J. Immunol. 199, 4476-87 (2012)
- 30. Martin, S. J., Henry, C. M., Cullen, S. P. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol. Cell. 46, 387-97 (2012)
- 31. Weiss, G., Shemer, A., Trau, H. The Koebner phenomenon: review of the literature. JEADV. 16, 241-248 (2002)
- 32. Schechter, I and Berger, A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun, 27(2):157-162. (1967)
- 33. Schechter, I. and Berger, A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem Biophys Res Commun, 32(5):898-902. (1968)
- 34. Bruno, B. J., Miller, G. D., Lim, C. S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4, 1443-67 (2013)
- 35. Powers J C1, Asgian J L, Ekici O D, James K E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-750. (2002)
- 36. Merrifield, R. B. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
- J. Am. Chem. Soc., 85, 2149-2154 (1963)
- 37. Nilsson, B. L., Soellner, M. B., Raines, R. T. Chemical Synthesis of Proteins. Annu. Rev. Biophys. Biomol. Struct 2005; 34: 91-118 (2005)
- The invention will now be described by the following numbered statements.
-
- 1. Use of an agent capable of inhibiting IL-36 proteolytic processing, including IL-36α, IL-36β and/or IL-36γ proteolytic processing, for the treatment and/or reduction of inflammation in a subject.
- 2. Use for the treatment according to
statement 1 wherein the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. - 3. Use for the treatment according to
statement - 4. Use for the treatment according to
statement 3 wherein the agent targets the protease cleavage sites within IL-36 and/or amino acid residues downstream and/or upstream of the cleavage site. - 5. Use for the treatment according to
statement 3 orstatement 4 wherein the agent targets the IL-368 protease cleavage site NPQR5 and/or one or more of upstream amino acid residues EAAP or the agent targets IL-36γ cleavage site GRAV15 and/or one or more of upstream amino acid residues YQSM. - 6. Use for the treatment according to
statement - 7. Use for the treatment according to
statement 6 wherein the IL-36 activating protease is selected from elastase, cathepsin G, cathepsin K or DPPI (Cathepsin C). - 8. Use for the treatment according to any of the preceding statements wherein the agent is a small molecule, peptide, polypeptide, protein, siRNA, sgRNA, and/or antibody.
- 9. Use for the
treatment according statement 6 wherein the peptide is at least a tripeptide or tetrapeptide or up to 8-10 peptide in length that binds the IL-36 activating protease and/or competes with IL-36 activating proteases for access to the IL-36 cleavage sites. - 10. Use for the treatment according to
statement 9 wherein the peptide is designed to mimic the protease cleavage sites within IL-36β and IL-36γ required for activation of IL-36 and bind the protease active site to inhibit its activity. - 11. Use for the treatment according to
statement 9 orstatement 10 wherein the peptide is selected from one or more of the following:- Glu-Pro-Phe;
- Ala-Phe-Leu-Phe;
- Lys-Ala-Leu;
- Glu-Pro-Phe-CMK;
- Ala-Phe-Leu-Phe-CMK;
- Lys-Ala-Leu-CMK,
- Arg-Ala-Val,
- Asp-Thr-Glu-Phe,
- Ala-Pro-Leu,
- Pro-Gln-Arg,
- Arg-Pro-Leu
- or chemically modified derivatives thereof or combinations thereof.
- 12. Use for the treatment according to any of the preceding statements wherein the agent is a small molecule inhibitor of cathepsin G and elastase, including serine protease inhibitors, optionally selected from Boswellic Acids, cathepsin G inhibitor I, Elastase inhibitor IV, Sodium Fluoride, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF.HCl), Aprotinin, Leupeptin, and/or phenylmethanesulfonylfluoride (PMSF).
- 13. Use for the treatment according to any of the preceding statements wherein the antibody is a polyclonal or monoclonal antibody raised against neutrophil-derived proteases, including the proteases elastase or cathepsin G or cathepsin K wherein the antibody binds to the protease to prevent its binding to the protease cleavage sites within IL-36 required for activation of IL-36.
- 14. Use according to any of the preceding statements for the treatment of inflammation of barrier organs in a subject, including inflammation of the skin, gut and/or lung, preferably inflammatory skin disorders, optionally selected from psoriasis, dermatitis and/or acne.
- 15. A composition, optionally a topical inflammatory skin disorder treatment, comprising an agent capable of inhibiting IL-36 proteolytic processing and a suitable pharmaceutical excipient.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/994,283 US20200384062A1 (en) | 2014-09-18 | 2020-08-14 | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14185397 | 2014-09-18 | ||
EP14185397.8 | 2014-09-18 | ||
PCT/EP2015/071446 WO2016042131A1 (en) | 2014-09-18 | 2015-09-18 | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
US201715512139A | 2017-03-17 | 2017-03-17 | |
US16/994,283 US20200384062A1 (en) | 2014-09-18 | 2020-08-14 | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/512,139 Division US10744179B2 (en) | 2014-09-18 | 2015-09-18 | Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing |
PCT/EP2015/071446 Division WO2016042131A1 (en) | 2014-09-18 | 2015-09-18 | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200384062A1 true US20200384062A1 (en) | 2020-12-10 |
Family
ID=51570335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/512,139 Active 2035-09-26 US10744179B2 (en) | 2014-09-18 | 2015-09-18 | Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing |
US16/994,283 Pending US20200384062A1 (en) | 2014-09-18 | 2020-08-14 | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/512,139 Active 2035-09-26 US10744179B2 (en) | 2014-09-18 | 2015-09-18 | Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing |
Country Status (3)
Country | Link |
---|---|
US (2) | US10744179B2 (en) |
EP (2) | EP3193906B1 (en) |
WO (1) | WO2016042131A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10821094B2 (en) * | 2016-01-13 | 2020-11-03 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
US11766467B2 (en) * | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
AU2019349958A1 (en) * | 2018-09-28 | 2021-05-06 | Kyowa Kirin Co., Ltd. | IL-36 antibodies and uses thereof |
JP2022514950A (en) | 2018-12-21 | 2022-02-16 | 23アンドミー・インコーポレイテッド | Anti-IL-36 antibody and how to use it |
CN115477686B (en) * | 2022-09-22 | 2024-01-30 | 北海黑珍珠海洋生物科技有限公司 | Pearl shell active peptide with whitening effect and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014151456A2 (en) * | 2013-03-15 | 2014-09-25 | The Jackson Laboratory | Treatment of inflammatory diseases |
US20140348859A1 (en) * | 2012-01-10 | 2014-11-27 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3724570A1 (en) | 1987-06-27 | 1989-01-05 | Bayer Ag | HUMAN APROTININ, WHOSE LYS REST IN POSITION 15 IS REPLACED BY ANOTHER PROTOGENIC AMINO ACID REST |
JPH01294635A (en) * | 1988-05-24 | 1989-11-28 | Rooman Kogyo:Kk | Pharmaceutical composition for local administration |
JP2569196B2 (en) * | 1990-03-29 | 1997-01-08 | 帝人株式会社 | Anti-human SLPI antibody and immunoassay for human SLPI |
GB9726114D0 (en) | 1997-12-11 | 1998-02-11 | Univ Manchester | Prevention and/or treatment of allergic conditions |
US7071299B2 (en) | 2000-06-21 | 2006-07-04 | Zymogenetics, Inc. | Peptide and polypeptide inhibitors of complement C1s |
US7459461B2 (en) | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
EP1493810A1 (en) | 2003-06-30 | 2005-01-05 | Gentium S.p.A. | DNA-based aptamers for human cathepsin G |
US20090054374A1 (en) | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
JPWO2009054454A1 (en) | 2007-10-24 | 2011-03-03 | 国立大学法人 東京医科歯科大学 | Modulator of signal transduction of Toll-like receptor containing cathepsin inhibitor as an active ingredient |
DE102009004436A1 (en) | 2008-10-15 | 2010-04-29 | Aureliasan Gmbh | Use of a tirucallic acid, a lupanic acid or a roburic acid and its salt, derivative or salt of the derivative as a medicament to treat pains, inflammations, fever, cancer, allergies, Crohn's disease, psoriasis and rheumatoid arthritis |
JP6294076B2 (en) * | 2011-01-06 | 2018-03-14 | ビオノール イミュノ エーエスBionor Immuno As | Multimeric peptide |
US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
-
2015
- 2015-09-18 WO PCT/EP2015/071446 patent/WO2016042131A1/en active Application Filing
- 2015-09-18 US US15/512,139 patent/US10744179B2/en active Active
- 2015-09-18 EP EP15763940.2A patent/EP3193906B1/en active Active
- 2015-09-18 EP EP20206694.0A patent/EP3831400A1/en not_active Withdrawn
-
2020
- 2020-08-14 US US16/994,283 patent/US20200384062A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140348859A1 (en) * | 2012-01-10 | 2014-11-27 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
WO2014151456A2 (en) * | 2013-03-15 | 2014-09-25 | The Jackson Laboratory | Treatment of inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
EP3193906A1 (en) | 2017-07-26 |
EP3193906B1 (en) | 2020-11-11 |
EP3831400A1 (en) | 2021-06-09 |
US20170281716A1 (en) | 2017-10-05 |
WO2016042131A1 (en) | 2016-03-24 |
US10744179B2 (en) | 2020-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200384062A1 (en) | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation | |
Henry et al. | Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines | |
Zheng et al. | Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation | |
Trapani | Granzymes: a family of lymphocyte granule serine proteases | |
de Rivero Vaccari et al. | A molecular platform in neurons regulates inflammation after spinal cord injury | |
Stehlik et al. | COPs and POPs: modulators of inflammasome activity | |
CN104661672B (en) | For preventing or treating the compositionss of septicemia | |
ES2316356T3 (en) | COMPLEMENTARY SYNTHETIC PEPTIDES AND ITS OPHTHALMOLOGICAL USES. | |
US20080261869A1 (en) | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity | |
US7718610B2 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
US20180008684A1 (en) | Compositions, methods and uses for alpha-1 antitrypsin or derivatives thereof | |
Lara‐Reyna et al. | Inflammasome activation: from molecular mechanisms to autoinflammation | |
US10550172B2 (en) | Serpin reactive center loop peptides and methods of use | |
AU2011383222B2 (en) | Modified peptides and their use for treating autoimmune diseases | |
US6713078B2 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
US8106019B2 (en) | CHEC-7 a novel sPLA2 inhibitor | |
US9617325B2 (en) | Treatment of IgE-mediated disease | |
US20180050082A1 (en) | Serpins for the treatment of neuroinflammatory diseases | |
Lara-Reyna et al. | Inflammasome activation | |
Dojo Soeandy | Regulation of necroptotic-apoptotic signaling in vitro and in vivo | |
Soeandy | Regulation of Necroptotic-Apoptotic Signaling In Vitro and In Vivo | |
Savage | Understanding how injured tissue communicates with the immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HO, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARTIN, SEAMUS J.;HENRY, CONOR;SULLIVAN, GRAEME;SIGNING DATES FROM 20170508 TO 20170509;REEL/FRAME:053504/0436 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |